COX20-Related COX Deficiency

🏷

Classifications

Harrison's Part

Mechanistic Nosology

ICIMD (Inherited Metabolic Disorders)

◆

Subtypes

3

Infantile hypotonia presentation

Infantile hypotonia and developmental or movement abnormalities without prominent neuropathy at assessment. Neuropathy can be absent or evolve later.

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6711551 SUPPORT REVIEW SYNTHESIS Human Clinical

"Only 3/27 patients (11.4%) presented with infantile hypotonia immediately after birth."

The authors proposed a descriptive phenotype cluster; boundaries are not a validated genotype-based taxonomy.

Childhood axonal neuropathy presentation

Childhood sensory-predominant axonal neuropathy, frequently with ataxia and variable motor involvement.

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6711551 SUPPORT REVIEW SYNTHESIS Human Clinical

"patients (20/27 patients, 74.1%) present with axonal neuropathy and associated clinical signs, with an onset age ranging from 1 to 17 years;"

The authors proposed a descriptive phenotype cluster; boundaries are not a validated genotype-based taxonomy.

Neuropathy and dystonia-ataxia overlap

Overlapping neuropathy, dystonia and cerebellar manifestations, often with later emergence of dystonia.

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6711551 SUPPORT REVIEW SYNTHESIS Human Clinical

"a third group (4/27 patients; 14.8%) present with a neuropathy/DYTCA overlapping syndrome with an onset age ranging from 1.9 to 12 years."

The authors proposed a descriptive phenotype cluster; boundaries are not a validated genotype-based taxonomy.

?

Discussions and Knowledge Gaps

1

Why do similar COX20 defects produce different central and peripheral neurological phenotypes?

OPEN QUESTION OPEN cox20-tissue-vulnerability

Cellular respiratory defects and large-fiber pathology support bioenergetic disease, but genotype-severity relationships and the selective vulnerability of sensory neurons remain unresolved. Mouse single-cell expression analysis suggests enrichment in proprioceptive populations; this is computational context rather than proof of a human cell-specific mechanism.

Show evidence (2 references)

url:https://oup.silverchair-cdn.com/article-minimal/6180070 SUPPORT Computational

"was preferentially expressed in two proprioceptive populations (termed NF4 and NF5)."

The result comes from reanalysis of a mouse dorsal-root-ganglion single-cell database.

url:https://oup.silverchair-cdn.com/article-minimal/6711551 SUPPORT REVIEW SYNTHESIS Human Clinical

"Unfortunately, a clear genotype/phenotype correlation could not be established"

The literature synthesis explicitly identifies this limitation.

⚙

Pathophysiology

11

Aberrant COX20 Splicing

Variants at or near splice donors reduce productive COX20 transcripts. The recurrent c.41A>G coding-position variant removes 20 bases from exon 1; c.157+3G>C promotes an exon-2-skipped noncoding transcript.

COX20 hgnc:26970

Downstream

COX20 Protein Deficiency Loss of productive transcript reduces COX20 abundance.

Show evidence (2 references)

PMID:35651336 SUPPORT In Vitro

"TA clone sequencing demonstrated that aligned with the reference sequence (NM_198076.6), the c.41A > G mutation led to a 20 bp deletion in exon 1."

Patient-fibroblast transcript sequencing demonstrates the splice effect of the coding-position variant.

PMID:30656193 SUPPORT In Vitro

"One variant (IVS2+3G>C), located near intron-2’s splice donor site, resulted in increased expression of the ΔEXON2 mRNA."

Patient RNA analysis identifies a distinct exon-2 splicing defect.

COX20 Protein Instability

S33L and W74C substitutions accelerate COX20 turnover in transfected cells. Mutant proteins retain mitochondrial inner-membrane localization.

COX20 hgnc:26970

Experimental models

COX20 splice and protein-stability assays CELL LINE Mutant constructs turn over faster than wild type.

Downstream

COX20 Protein Deficiency Accelerated turnover reduces steady-state COX20 abundance.

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6180070 SUPPORT In Vitro

"mutant COX20, especially W74C-COX20, were degraded faster than wild-type, suggesting that the two missense variants affected the protein half-life of COX20."

Cycloheximide-chase experiments support instability of S33L and W74C proteins.

COX20 Protein Deficiency

Loss of functional COX20 removes a COX2-specific chaperone and assembly adaptor. Patient fibroblasts can have nearly absent protein despite normal routine respiratory-enzyme assays.

COX20 hgnc:26970

COX20-dependent presentation of COX2 to maturation partners GO:0030674 ↓ DECREASED

Downstream

COX2 Instability Loss of COX20 destabilizes newly synthesized COX2 in engineered human cells.

Impaired COX2 Maturation Loss of the chaperone limits presentation of COX2 to its metallochaperone machinery.

Show evidence (3 references)

PMID:30656193 SUPPORT In Vitro

"Consistent with this finding, protein analysis revealed no detectable COX20 protein present"

Immunoblotting of patient fibroblasts demonstrates loss of detectable COX20.

PMID:24403053 SUPPORT INDIRECT In Vitro

"We propose that COX20 acts as a chaperone in the early steps of COX2 maturation, stabilizing the newly synthesized protein and presenting COX2 to its metallochaperone module"

Protein-interaction experiments motivate the COX2 presentation model; direct copper transport by COX20 is not established.

PMID:31079202 SUPPORT Human Clinical

"decreased COX20 protein level of peripheral blood leucocytes derived from the patients"

Reduced protein in patient-derived blood leucocytes provides uncultured human-tissue evidence, complementing the fibroblast experiments.

COX2 Instability

Newly synthesized COX2 turns over rapidly in COX20-depleted HEK293T cells. This model result is not uniform across patient cultures: two 2021 patient lines retained normal steady-state COX2.

Experimental models

COX20-depleted HEK293T cells CELL LINE Pulse-chase analysis shows rapid COX2 turnover.

Downstream

Reduced Complex IV Assembly Reduced stable COX2 limits incorporation into the holoenzyme.

Show evidence (2 references)

PMID:24403053 SUPPORT In Vitro

"newly synthesized COX2 is unstable and most of it is rapidly degraded within 2 h of the chase"

Pulse-chase analysis in COX20-silenced cells identifies reduced COX2 stability rather than a primary synthesis defect.

url:https://oup.silverchair-cdn.com/article-minimal/6180070 REFUTE In Vitro

"Western blot analysis revealed COX2 protein was not affected in the fibroblasts of Patients 1 and 5."

The patient lines refute a universal reduction in steady-state COX2.

Impaired COX2 Maturation

COX20-bound COX2 interacts with SCO1/SCO2 during maturation. Co-immunoprecipitation supports coordination of this machinery; it does not prove direct COX20-SCO binding or quantify copper loading.

Downstream

Reduced Complex IV Assembly Failure to supply mature COX2 limits complex IV biogenesis.

Show evidence (1 reference)

PMID:24403053 SUPPORT INDIRECT In Vitro

"We propose that COX20 acts as a chaperone in the early steps of COX2 maturation, stabilizing the newly synthesized protein and presenting COX2 to its metallochaperone module"

Protein-interaction experiments motivate the COX2 presentation model; direct copper transport by COX20 is not established.

Reduced Complex IV Assembly

COX1-containing intermediates accumulate and the mature complex IV pool decreases when COX2 incorporation is impaired.

COX20 hgnc:26970

mitochondrial respiratory chain complex IV assembly GO:0033617 ↓ DECREASED

Experimental models

COX20-depleted HEK293T cells CELL LINE Engineered cells accumulate assembly intermediates.

Patient fibroblast complementation PRIMARY CELL CULTURE Wild-type COX20 increases assembled complex IV.

Downstream

Reduced Complex IV Activity The reduction in assembled enzyme limits terminal respiratory-chain activity.

Show evidence (2 references)

PMID:23125284 SUPPORT In Vitro

"Cells affected by the mutation accumulate subassemblies of complex IV that contain COX1 but are almost devoid of COX2 protein."

Patient-fibroblast subassemblies demonstrate failed incorporation of COX2.

PMID:35651336 SUPPORT In Vitro

"These findings demonstrate that COX20 variants led to a specific reduction of CIV levels and very low residual levels of fully assembled CIV"

Blue-native electrophoresis establishes reduced assembled complex IV in patient fibroblasts.

Reduced Complex IV Activity

Complex IV enzyme activity is reduced in patient fibroblasts and engineered cells. Residual activity, tissue dependence and occasional additional complex abnormalities preclude a universal complete or strictly isolated deficiency.

mitochondrial electron transport, cytochrome c to oxygen GO:0006123 ↓ DECREASED

Animal models

Saccharomyces cerevisiae cox20 deletion Saccharomyces cerevisiae recapitulates The model reproduces impaired respiratory function associated with Cox20 loss.

Downstream

Reduced Respiratory Reserve Reduced terminal electron transport constrains oxidative respiratory capacity.

Show evidence (1 reference)

PMID:35651336 SUPPORT In Vitro

"The enzyme activities of complex IV were lower in the patient's cells than in control cells"

Patient-fibroblast enzyme assays establish reduced complex IV activity.

Reduced Respiratory Reserve

COX20-silenced sensory-neuron-like cells show reduced ATP-linked respiration, maximal respiration and spare capacity. Patient fibroblasts also show impaired oxidative phosphorylation.

mitochondrial ATP synthesis coupled electron transport GO:0042775 ↓ DECREASED

Experimental models

Patient fibroblast complementation PRIMARY CELL CULTURE Adenoviral COX20 partially restores mitochondrial function.

COX20-silenced ND7/23 cells CELL LINE Knockdown reduces ATP-linked respiration and reserve.

Downstream

Reduced Cellular Stress Tolerance Reduced energetic reserve accompanies impaired growth under metabolic challenge.

Neurological Dysfunction Cellular bioenergetic defects are a plausible basis of the clinical neurological syndrome; tissue-specific intermediate steps remain incompletely resolved.

Show evidence (2 references)

url:https://oup.silverchair-cdn.com/article-minimal/6180070 SUPPORT In Vitro

"knockdown of COX20 expression resulted in the reduction of ATP-linked OCR and maximal respiration OCR, indicating a lower spare respiratory capacity."

Respirometry demonstrates reduced ATP-linked respiration and reserve in ND7/23 cultures; it does not establish total ATP collapse.

PMID:35651336 SUPPORT In Vitro

"Basal respiration, maximal respiration, ATP production, and spare respiratory capacity of fibroblasts from the patient are significantly lower than those of control."

The independent patient-fibroblast study confirms bioenergetic impairment.

Reduced Cellular Stress Tolerance

Knockdown reduces ND7/23 proliferation under galactose challenge and, in the stronger knockdown clone, viability after peroxide exposure. These culture experiments do not directly demonstrate neuronal death in patients.

Experimental models

COX20-silenced ND7/23 cells CELL LINE Galactose challenge accentuates the growth defect.

Downstream

Neurological Dysfunction Reduced cellular resilience could contribute to progressive neural dysfunction; the in-vivo connection remains an inference.

Show evidence (2 references)

url:https://oup.silverchair-cdn.com/article-minimal/6180070 SUPPORT In Vitro

"growth rate was significantly lower in siCOX20 cells than that in control cells in regular glucose medium, and further decreased in oxidative phosphorylation-promoting galactose media."

COX20 silencing impairs cultured-cell growth, particularly when oxidative phosphorylation is required.

url:https://oup.silverchair-cdn.com/article-minimal/6180070 SUPPORT In Vitro

"significantly suppressed the cell viability in siCOX20-2 cells"

Hydrogen peroxide exposure reduced viability in the stronger knockdown clone.

Neurological Dysfunction

Central and peripheral neurological involvement varies across patients, including sensory neuronopathy, movement abnormalities, motor impairment and cognitive symptoms. The intervening tissue-specific consequences of respiratory dysfunction are incompletely defined.

Downstream

Large Sensory Fiber Loss Peripheral neural involvement includes loss of large myelinated fibers.

Hypotonia The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.

Ataxia The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.

Dysarthria The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.

Dystonia The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.

Limb Weakness The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.

Motor Delay The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.

Intellectual Disability The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.

Spasticity The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.

Visual Impairment The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.

External Ophthalmoplegia The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.

Cerebellar Atrophy The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.

Cervical Spinal Cord Atrophy The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.

Cerebral Atrophy Central involvement can include structural cerebral loss; the cellular intermediates remain unresolved.

Static Encephalopathy Central dysfunction can present as static encephalopathy; specific intervening tissue mechanisms are not established.

Show evidence (1 reference)

PMID:41010014 SUPPORT Human Clinical

"The patient exhibited progressive ataxia, pyramidal signs, and peripheral neuropathy, accompanied by cervical spinal cord atrophy"

The adult case documents combined central and peripheral involvement.

Large Sensory Fiber Loss

Sural nerve pathology shows depletion of large myelinated fibers. Non-length-dependent sensory potentials and proprioceptive loss support a sensory neuronopathy in a subset, although direct dorsal-root-ganglion pathology has not been demonstrated in these patients.

sensory neuron CL:0000101

Downstream

Sensory Axonal Neuropathy Large-fiber loss accompanies severe sensory nerve-conduction abnormalities.

Impaired Proprioception Large sensory-fiber dysfunction impairs position sense.

Impaired Vibration Sense Large sensory-fiber dysfunction impairs vibration sense.

Areflexia Loss of sensory input can impair the reflex arc.

Show evidence (2 references)

PMID:35651336 SUPPORT Human Clinical

"Pronounced depletion of large myelinated fibers by approximately 80% in the MGT-stained sural nerve"

The proband biopsy documents large-fiber loss; this does not by itself establish primary demyelination.

PMID:33751098 SUPPORT Human Clinical

"All patients displayed sensory ataxia with a decrease in non-length-dependent sensory potentials."

The eight-family cohort establishes sensory neuronopathy, with ascertainment focused on that presentation.

✶

Histopathology

3

Large myelinated nerve-fiber depletion

Sural nerve biopsy can show marked depletion of large myelinated fibers, with axonal degeneration in the 2021 series. Fiber loss alone should not be interpreted as proof of primary demyelination.

Show evidence (2 references)

PMID:35651336 SUPPORT Human Clinical

"Pronounced depletion of large myelinated fibers by approximately 80% in the MGT-stained sural nerve"

The proband biopsy documents large-fiber loss; this does not by itself establish primary demyelination.

url:https://oup.silverchair-cdn.com/article-minimal/6180070 SUPPORT Human Clinical

"Sural nerve biopsy in Patient 5 showed marked loss of large and medium myelinated fibres and chronic axonal degeneration"

The independent biopsy supports chronic axonal pathology.

Muscle denervation atrophy

Angulated atrophic muscle fibers without ragged-red fibers were seen in the older sibling in the 2022 visual-impairment report.

Show evidence (1 reference)

PMID:35651336 SUPPORT Human Clinical

"numerous angulated atrophic fibers with an angular shape and decreased size, indicating atrophic fibers and denervation atrophy"

Muscle histology documents denervation rather than a universal primary myopathic pattern.

Abnormal mitochondrial morphology in sural nerve

The Xu family report described abnormal mitochondrial morphology in sural nerve tissue. Its abstract does not resolve the detailed ultrastructural changes.

Show evidence (1 reference)

PMID:31079202 SUPPORT Human Clinical

"morphological alternations of mitochondria observed in sural nerve"

The source reports a morphological abnormality in patient nerve tissue; the source spelling is preserved.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

31

Ear 1

Hearing Impairment HP:0000365

Show evidence (1 reference)

PMID:32999401 SUPPORT Human Clinical

"An 18-year-old girl with sensory neuropathy, ataxia, distal extremity weakness, spasticity, and hearing loss"

The COX20-specific case paragraph, rather than the mixed-gene cohort total, supports hearing impairment.

Eye 4

External Ophthalmoplegia HP:0000544

Show evidence (2 references)

url:https://oup.silverchair-cdn.com/article-minimal/6711551 SUPPORT REVIEW SYNTHESIS Human Clinical

"The most frequent clinical features are neuropathy (24/27), ataxia (20/27), dysarthria (16/27), hypotonia (10/27), dystonia (6/27) and ophthalmoplegia (6/27)."

These are descriptive counts in the 27-case literature compilation, not population frequencies.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1224/ SUPPORT BACKGROUND Other

"Common clinical features of mitochondrial disorders include ptosis, external ophthalmoplegia, proximal myopathy and exercise intolerance"

General mitochondrial context, not a COX20-specific frequency estimate.

Visual Impairment HP:0000505

Show evidence (1 reference)

PMID:35651336 SUPPORT Human Clinical

"Her visual acuity in the right eye was reduced to counting fingers and to 0.15 in the left eye."

The older sibling had marked visual loss.

Strabismus HP:0000486

Show evidence (1 reference)

PMID:35651336 SUPPORT Human Clinical

"Left-sided ptosis and strabismus were observed at first sight"

The older sibling had both ocular findings.

Ptosis HP:0000508

Show evidence (1 reference)

PMID:35651336 SUPPORT Human Clinical

"Left-sided ptosis and strabismus were observed at first sight"

The clinical examination documents left ptosis.

Head and Neck 1

Microcephaly HP:0000252

Show evidence (1 reference)

PMID:30656193 SUPPORT BACKGROUND Human Clinical

"One family had a child with additional findings of microcephaly, mildly elevated serum and CSF lactate, and a normal brain MRI."

Otero summarizes the founding case; this is secondary clinical evidence.

Limbs 4

Limb Weakness Limb muscle weakness HP:0003690

Show evidence (1 reference)

PMID:35651336 SUPPORT Human Clinical

"Profound symmetric proximal muscle weakness of the lower limbs with 2–3/5 grades using the Medical Research Council (MRC) scale was noted."

The older sibling had severe proximal lower-limb weakness.

Pes Cavus HP:0001761

Show evidence (1 reference)

PMID:30656193 SUPPORT Human Clinical

"Her left foot had a pes cavus deformity."

Subject 1 had unilateral cavus deformity.

Pes Planus HP:0001763

Show evidence (1 reference)

PMID:35651336 SUPPORT Human Clinical

"On neurological examination at 6 years, leg dystonia was observed, and she was found to be flat-footed"

The younger sibling had pes planus.

Foot Drop Foot dorsiflexor weakness HP:0009027

Show evidence (1 reference)

PMID:30656193 SUPPORT Human Clinical

"She developed bilateral foot drop at age 11 years."

Subject 2 developed bilateral foot drop.

Metabolism 1

Elevated Lactate Increased circulating lactate concentration HP:0002151

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6711551 SUPPORT REVIEW SYNTHESIS Human Clinical

"Standard laboratory analyses detected mildly elevated serum lactate levels in 4/17 of patients (23.5%)"

The count is limited to tested published cases.

Musculoskeletal 3

Hypotonia HP:0001252

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6711551 SUPPORT REVIEW SYNTHESIS Human Clinical

"The most frequent clinical features are neuropathy (24/27), ataxia (20/27), dysarthria (16/27), hypotonia (10/27), dystonia (6/27) and ophthalmoplegia (6/27)."

These are descriptive counts in the 27-case literature compilation, not population frequencies.

Context-specific annotations (1)

Infantile hypotonia presentation

Early hypotonia defines this proposed presentation; this does not restrict hypotonia to it.

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6711551 SUPPORT REVIEW SYNTHESIS Human Clinical

"Only 3/27 patients (11.4%) presented with infantile hypotonia immediately after birth."

The 2022 authors characterize this descriptive clinical presentation.

Spasticity HP:0001257

Show evidence (1 reference)

PMID:30656193 SUPPORT Human Clinical

"Her gait was significant for some toe walking associated with spasticity."

Subject 1 showed spasticity.

Painful Muscle Spasms HP:0003394

Show evidence (1 reference)

PMID:30656193 SUPPORT Human Clinical

"In her 20s, she developed painful muscle spasms that were treated with baclofen."

Subject 2 developed painful spasms; the source does not establish that spasticity was the treated symptom.

Nervous System 16

Ataxia HP:0001251

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6711551 SUPPORT REVIEW SYNTHESIS Human Clinical

"The most frequent clinical features are neuropathy (24/27), ataxia (20/27), dysarthria (16/27), hypotonia (10/27), dystonia (6/27) and ophthalmoplegia (6/27)."

These are descriptive counts in the 27-case literature compilation, not population frequencies.

Dysarthria HP:0001260

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6711551 SUPPORT REVIEW SYNTHESIS Human Clinical

"The most frequent clinical features are neuropathy (24/27), ataxia (20/27), dysarthria (16/27), hypotonia (10/27), dystonia (6/27) and ophthalmoplegia (6/27)."

These are descriptive counts in the 27-case literature compilation, not population frequencies.

Dystonia HP:0001332

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6711551 SUPPORT REVIEW SYNTHESIS Human Clinical

"The most frequent clinical features are neuropathy (24/27), ataxia (20/27), dysarthria (16/27), hypotonia (10/27), dystonia (6/27) and ophthalmoplegia (6/27)."

These are descriptive counts in the 27-case literature compilation, not population frequencies.

Context-specific annotations (1)

Neuropathy and dystonia-ataxia overlap

This proposed overlap cluster had later dystonia; the medians describe the reported cases, not individual prognosis.

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6711551 SUPPORT REVIEW SYNTHESIS Human Clinical

"this subgroup had a later age of onset, starting with neuropathy (median 7 years), dystonia (median 12 years) and dysarthria (median 13 years)."

The 2022 authors characterize this descriptive clinical presentation.

Sensory Axonal Neuropathy HP:0003390

Sequelae: Ataxia

Show evidence (2 references)

PMID:33751098 SUPPORT Human Clinical

"All patients displayed sensory ataxia with a decrease in non-length-dependent sensory potentials."

The eight-family cohort establishes sensory neuronopathy, with ascertainment focused on that presentation.

url:https://oup.silverchair-cdn.com/article-minimal/6711551 SUPPORT REVIEW SYNTHESIS Human Clinical

"8/19 had normal/decreased motor conduction velocities (MCV) plus low CMAP amplitude, compatible with mixed sensorimotor axonal neuropathy."

Motor involvement in the pooled literature prevents treating COX20 disease as invariably pure sensory neuropathy.

Context-specific annotations (1)

Childhood axonal neuropathy presentation

The proposed neuropathy presentation includes both sensory-only and sensorimotor findings.

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6711551 SUPPORT REVIEW SYNTHESIS Human Clinical

"patients in this phenotypical subgroup had severe axonal neuropathy (15/20 mixed motor sensory neuropathy and 5/20 pure sensory neuropathy)"

The 2022 authors characterize this descriptive clinical presentation.

Areflexia HP:0001284

Show evidence (1 reference)

PMID:37095481 SUPPORT Human Clinical

"A neurological examination performed on him, revealed hypotonia, Romberg sign, and the absence of deep tendon reflexes."

The child had absent deep tendon reflexes.

Impaired Proprioception HP:0010831

Sequelae: Ataxia

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6180070 SUPPORT Human Clinical

"early-onset progressive sensory ataxia, loss of position and vibration sense, absent tendon reflexes"

The cohort phenotype includes loss of position and vibration sense.

Impaired Vibration Sense Impaired vibratory sensation HP:0002495

Sequelae: Ataxia

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6180070 SUPPORT Human Clinical

"early-onset progressive sensory ataxia, loss of position and vibration sense, absent tendon reflexes"

The cohort phenotype includes vibration loss.

Motor Delay HP:0001270

Show evidence (1 reference)

PMID:35651336 SUPPORT Human Clinical

"Her motor development milestone was delayed. She was unable to walk until 1.5 years"

The younger sibling had motor delay.

Intellectual Disability HP:0001249

Show evidence (1 reference)

PMID:30656193 SUPPORT Human Clinical

"He had mild cognitive disability and required special education throughout his schooling."

Subject 3 had a persistent mild cognitive disability.

Cerebellar Atrophy HP:0001272

Show evidence (1 reference)

PMID:32606554 SUPPORT Human Clinical

"Cerebral magnetic resonance imaging (MRI) showed cerebellar atrophy"

The Turkish child had cerebellar atrophy with normal nerve-conduction studies.

Cervical Spinal Cord Atrophy HP:0010873

Show evidence (1 reference)

PMID:41010014 SUPPORT Human Clinical

"Spinal cord MRI performed at the age of 20 years demonstrated cervical and thoracic cord atrophy"

The adult case directly documents the cervical localization.

Chorea HP:0002072

Show evidence (1 reference)

PMID:30656193 SUPPORT Human Clinical

"He also developed frequent choreiform movements."

Subject 3 had choreiform movements.

Intention Tremor HP:0002080

Show evidence (1 reference)

PMID:32606554 SUPPORT Human Clinical

"he had dysarthria, bilateral dysmetria, intention tremor, dysdiadochokinesia, and gait ataxia."

The case documents intention tremor.

Depression HP:0000716

Show evidence (1 reference)

PMID:30656193 SUPPORT Human Clinical

"she developed depression, which responded to Selective Serotonin Reuptake Inhibitor treatment"

Subject 2 had depression with a reported treatment response.

Cerebral Atrophy HP:0002059

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6711551 SUPPORT REVIEW SYNTHESIS Human Clinical

"Brain MRIs showed marginal cerebral atrophy in five patients and cerebellar atrophy in two patients."

The literature compilation documents cerebral involvement.

Static Encephalopathy HP:0001298

Course: STABLE

Show evidence (1 reference)

PMID:31079202 SUPPORT Human Clinical

"two patients from a non-consanguineous family exhibiting autosomal recessive sensory-dominant axonal neuropathy and static encephalopathy"

Xu et al. describe static encephalopathy in two siblings; this is distinct from progressive gait impairment or a generic intellectual-disability label.

Constitutional 1

Urinary Incontinence HP:0000020

Show evidence (1 reference)

PMID:30656193 SUPPORT Human Clinical

"She became nonambulatory and developed incontinence at 19 years."

Subject 2 developed incontinence; subject 4 also had bladder-control difficulties.

🧬

Genetic Associations

1

Biallelic COX20 variants

Gene: COX20 hgnc:26970 gene page relationship_type: CAUSATIVE variant_origin: GERMLINE

Autosomal recessive

Show evidence (1 reference)

PMID:33751098 SUPPORT Human Clinical

"We identified eight unrelated families from the eastern Chinese population carrying a founder variant c.41A>G (p.Lys14Arg) within COX20 in either a homozygous or compound heterozygous state."

The shared haplotype supports a founder allele in this cohort, not a disease prevalence estimate.

Variants (8)

COX20 c.41A>G (p.Lys14Arg)

Gene: COX20 hgnc:26970 single nucleotide variant

Recurrent coding-position splice-disrupting variant; exon-1 deletion creates p.Gly8ValfsTer2. A protein-only K14R construct does not reproduce the splice effect.

Show evidence (2 references)

PMID:35651336 SUPPORT In Vitro

"TA clone sequencing demonstrated that aligned with the reference sequence (NM_198076.6), the c.41A > G mutation led to a 20 bp deletion in exon 1."

Patient-fibroblast transcript sequencing demonstrates the splice effect of the coding-position variant.

PMID:31079202 SUPPORT Human Clinical

"sequencing analysis revealed that both patients harbored compound heterozygous mutations (p.Lys14Arg and p.Trp74Cys) of COX20 gene."

The 2019 report supplies the original compound-heterozygous family observation, separately from later functional studies.

COX20 c.157+3G>C

Gene: COX20 hgnc:26970 single nucleotide variant

Genomic context: intron

Splice-donor-region variant associated with exon-2 skipping and loss of full-length RNA.

Show evidence (1 reference)

PMID:30656193 SUPPORT In Vitro

"One variant (IVS2+3G>C), located near intron-2’s splice donor site, resulted in increased expression of the ΔEXON2 mRNA."

Patient RNA supports altered splicing.

COX20 c.154A>C (p.Thr52Pro)

Gene: COX20 hgnc:26970 single nucleotide variant

Founding homozygous variant with reduced protein and altered transcript splicing.

Show evidence (1 reference)

PMID:24202787 SUPPORT Human Clinical

"By exome sequencing, we identified a homozygous missense mutation (c.154A >C; p.Thr52Pro) in both patients in exon 2 of the COX20 (FAM36A) gene"

The two siblings carried the founding allele.

COX20 p.Ser33Leu and p.Trp74Cys

Gene: COX20 hgnc:26970 single nucleotide variant

Missense substitutions with accelerated turnover in expression assays; W74C is encoded by c.222G>T.

Show evidence (2 references)

url:https://oup.silverchair-cdn.com/article-minimal/6180070 SUPPORT In Vitro

"mutant COX20, especially W74C-COX20, were degraded faster than wild-type, suggesting that the two missense variants affected the protein half-life of COX20."

Cycloheximide-chase experiments support instability of S33L and W74C proteins.

PMID:31079202 SUPPORT Human Clinical

"sequencing analysis revealed that both patients harbored compound heterozygous mutations (p.Lys14Arg and p.Trp74Cys) of COX20 gene."

The 2019 report supplies the original compound-heterozygous family observation, separately from later functional studies.

COX20 c.157+7A>G

Gene: COX20 hgnc:26970 single nucleotide variant

Genomic context: intron

A minigene assay, performed because patient RNA was unavailable, showed exon-2 skipping.

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6180070 SUPPORT In Vitro

"variant therefore caused the skipping of exon 2 resulting in a premature stop codon p.Ser15Valfs*11."

The result is from a transfected minigene, not patient RNA.

COX20 c.42+1G>A

Gene: COX20 hgnc:26970 single nucleotide variant

Genomic context: intron

Splice-donor variant reported in trans with c.41A>G; both affect the exon-1 donor.

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6711551 SUPPORT In Vitro

"cause a uniform splice defect of exon 1 resulting in a 20-base pair cDNA deletion at the 3′ end in more than 90% of the transcripts"

Patient RNA/proteomics support the combined splice defect.

COX20 c.259C>T (p.Gln87Ter)

Gene: COX20 hgnc:26970 single nucleotide variant

Nonsense allele found in trans with c.41A>G in multiple families.

Show evidence (1 reference)

PMID:39897410 SUPPORT Human Clinical

"whole-exome sequencing (WES) revealed compound heterozygous mutations in the COX20 gene (c.41A>G, p.Lys14Arg and c.259C>T, p.Gln87Ter)"

The prenatal-counseling family supplies unambiguous variant notation.

COX20 c.2T>C (p.Met1?)

Gene: COX20 hgnc:26970 single nucleotide variant

Start-loss allele reported in a 2025 patient on NM_198076.6. The authors classified it as pathogenic, while earlier ClinVar submissions were uncertain; complete loss of expression was predicted rather than experimentally shown.

Show evidence (1 reference)

PMID:41010014 SUPPORT Computational

"In silico analysis revealed the absence of downstream in-frame methionine codons"

The proposed loss of translation rests on sequence analysis, not a functional protein assay.

💊

Medical Actions

10

Rehabilitation and communication support

Action: Rehabilitation NCIT:C15315

Physical, occupational and speech therapies support mobility, daily activities and communication. Mobility aids and orthotic assessment can be individualized; these measures have not been shown to stop COX20 disease progression.

Target Phenotypes: Ataxia HP:0001251 Limb muscle weakness HP:0003690 Dysarthria HP:0001260 Foot dorsiflexor weakness HP:0009027

Show evidence (2 references)

PMID:28749475 SUPPORT REVIEW SYNTHESIS Other

"Therapy services including physical therapy, occupational therapy, and speech therapy"

The general mitochondrial consensus identifies these supportive services.

PMID:39897410 SUPPORT Human Clinical

"Despite intermittent treatment with L-carnitine and rehabilitation training, the patient’s symptoms progressed."

Rehabilitation use in this child did not establish a disease-modifying effect.

Levodopa trial for dystonia

Action: Pharmacotherapy NCIT:C15986

Agent: Levodopa NCIT:C611

Platform: Small molecule

Responses differ. One six-year-old had improved gait for five months; her older sister did not respond to high-dose levodopa. Another patient did not respond to carbidopa/levodopa. These case observations support individualized assessment, not a predictable sustained benefit.

Target Phenotypes: Dystonia HP:0001332

Show evidence (3 references)

PMID:35651336 SUPPORT Human Clinical

"Treatment with 62.5 mg levodopa effectively improved her gait but the effect lasted for only 5 months."

A transient symptomatic benefit was reported in the younger sibling.

PMID:35651336 REFUTE Human Clinical

"Treatment with a high dose of L-DOPA was ineffective."

The older sibling did not respond.

PMID:30656193 REFUTE Human Clinical

"episodic dystonic posturing of her feet, which did not respond to carbidopa/levodopa treatment."

Another patient had no reported dystonia benefit.

Baclofen for painful spasms

Action: Pharmacotherapy NCIT:C15986

Agent: Baclofen NCIT:C28858

Platform: Small molecule

Baclofen has been used for painful muscle spasms. The published case does not quantify efficacy.

Target Phenotypes: Painful muscle spasms HP:0003394

Show evidence (1 reference)

PMID:30656193 SUPPORT Human Clinical

"In her 20s, she developed painful muscle spasms that were treated with baclofen."

The source documents use, not a demonstrated response.

Mental-health treatment

Action: Pharmacotherapy NCIT:C15986

Agent: Selective Serotonin Reuptake Inhibitor NCIT:C94725

Assess mood, cognition and behavior. Depression improved with an SSRI in one patient; later psychiatric symptoms required additional treatment. Medication choice and monitoring are individualized.

Target Phenotypes: Depression HP:0000716

Show evidence (1 reference)

PMID:30656193 SUPPORT Human Clinical

"she developed depression, which responded to Selective Serotonin Reuptake Inhibitor treatment"

The report documents a symptomatic antidepressant response.

Empirical mitochondrial supplements

Action: Nutritional Support NCIT:C15433

Agent: (R)-carnitine CHEBI:16347 Coenzyme Q10 NCIT:C916 Idebenone NCIT:C74158 thiamine(1+) CHEBI:18385

Coenzyme Q10 or idebenone, carnitine and vitamin combinations have been tried without consistent benefit. Reported two-year stability during supplementation can reflect natural history. These regimens are not established disease-modifying therapies.

Show evidence (3 references)

PMID:37095481 REFUTE Human Clinical

"L-carnitine and coenzyme Q10 were administered to the patient, but the medication had no effect."

The child had no reported benefit from this combination.

url:https://oup.silverchair-cdn.com/article-minimal/6711551 REFUTE REVIEW SYNTHESIS Human Clinical

"None showed any benefit from treatment."

The immediately preceding paragraph describes two vitamin B1/idebenone/L-carnitine regimens and two muscle-relaxant regimens; these small observations do not establish universal inefficacy.

PMID:41010014 REFUTE Human Clinical

"Although no clinical improvement was observed, the patient’s condition remained stable throughout the two-year observation period. This stability, however, could be consistent with the natural history of the disease."

The adult case does not establish that supplementation caused stability.

Ophthalmological surveillance and visual support

Action: Supportive Care NCIT:C15747

Assess acuity, ocular alignment and eye movements, and provide appropriate visual support. General mitochondrial guidance recommends ophthalmology assessment at diagnosis and annual follow-up; COX20-specific surveillance intervals have not been tested.

Target Phenotypes: Visual impairment HP:0000505 External ophthalmoplegia HP:0000544 Strabismus HP:0000486 Ptosis HP:0000508

Show evidence (1 reference)

PMID:28749475 SUPPORT REVIEW SYNTHESIS Other

"Annual ophthalmology exams should be conducted thereafter."

This follows the recommendation for neuro-ophthalmology assessment at diagnosis in general mitochondrial disease.

Hearing assessment and rehabilitation

Action: Rehabilitation NCIT:C15315

Assess reported hearing difficulty and provide amplification when appropriate. These care options are extrapolated from general mitochondrial guidance.

Target Phenotypes: Hearing impairment HP:0000365

Show evidence (1 reference)

PMID:28749475 SUPPORT REVIEW SYNTHESIS Other

"Moderate to severe hearing loss should be treated with digital hearing aids to improve function; when profound, cochlear implantation should be considered."

General mitochondrial guidance supports hearing rehabilitation; COX20-specific treatment outcomes are unavailable.

Multisystem surveillance

Action: Supportive Care NCIT:C15747

Coordinate neurological, mobility, visual, hearing, cognitive and psychiatric follow-up. Broader mitochondrial guidance also supports cardiac and metabolic screening according to clinical context; these recommendations do not imply that each complication is common in COX20 deficiency.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1224/ SUPPORT REVIEW SYNTHESIS Other

"These focus on regular surveillance to detect complications and their management using standard approaches that are not usually specific to mitochondrial disorders."

GeneReviews frames supportive care and surveillance.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1224/ SUPPORT REVIEW SYNTHESIS Other

"Regular cardiac evaluation and monitoring for diabetes are particularly important."

General mitochondrial surveillance is distinguished from COX20-specific phenotype frequencies.

Illness and perioperative planning

Action: Supportive Care NCIT:C15747

Develop an individualized emergency plan, avoid prolonged fasting and review drug and anesthetic risks. Glucose-containing fluids require clinical adjustment for contraindications or prior adverse responses. Avoid prolonged propofol infusion where possible.

Show evidence (3 references)

PMID:28749475 SUPPORT REVIEW SYNTHESIS Other

"Patients with a mitochondrial disease should carry an emergency care plan that details their underlying disorder and provides management recommendations."

General mitochondrial guidance supports advance planning.

PMID:28749475 SUPPORT REVIEW SYNTHESIS Other

"Patients should minimize preoperative fasting and have glucose added to their perioperative IV fluids, unless they are on a ketogenic diet or have been demonstrated to have adverse reaction to higher glucose intake."

Perioperative recommendations carry important exceptions.

PMID:28749475 SUPPORT REVIEW SYNTHESIS Other

"Mitochondrial patients may be at a higher risk for propofol infusion syndrome and propofol use should be avoided or limited to short procedures."

General anesthetic caution is not a reported COX20-specific adverse event.

Genetic and reproductive counseling

Action: Genetic Counseling NCIT:C15240

Confirm parental segregation and discuss the 25% affected risk per pregnancy when both parents carry causative alleles. Familial carrier testing, prenatal diagnosis and preimplantation testing are options according to family preferences; a published COX20 family underwent prenatal diagnosis, not preimplantation testing.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1224/ SUPPORT REVIEW SYNTHESIS Other

"Carrier testing for at-risk relatives requires prior identification of the causative pathogenic variants in the family."

General recessive mitochondrial counseling supports targeted familial testing.

PMID:39897410 SUPPORT REVIEW SYNTHESIS Other

"parents may opt for preimplantation genetic diagnosis (PGD) during in vitro fertilization (IVF)"

The report discusses a reproductive option rather than documenting its use in this family.

🔬

Biochemical Markers

2

Reduced complex IV activity (Variable)

Context: Assay and tissue dependent; muscle and some fibroblast lines are abnormal, while other fibroblast assays are normal.

Show evidence (2 references)

PMID:35651336 SUPPORT In Vitro

"The enzyme activities of complex IV were lower in the patient's cells than in control cells"

Patient-fibroblast enzyme assays establish reduced complex IV activity.

url:https://oup.silverchair-cdn.com/article-minimal/6711551 REFUTE REVIEW SYNTHESIS In Vitro

"normal OXPHOS activity in the fibroblasts of three patients"

These cultured-fibroblast results refute universal assay-detectable deficiency. Together with reduced activity in other tissues and lines they support the Variable presence annotation, not reduced activity in these three cultures.

Reduced muscle coenzyme Q10 (Reported in a family)

Context: Documented in the Turkish sibling report; not established as a universal biochemical feature.

Show evidence (1 reference)

PMID:24202787 SUPPORT Human Clinical

"Biochemical analyses revealed a mitochondrial respiratory chain complex IV and a coenzyme Q10 deficiency in a muscle biopsy."

The muscle assay found both abnormalities.

🔬

Diagnosis

6

Molecular confirmation

Identify biallelic causative COX20 variants with a panel that includes COX20, exome or genome sequencing, and segregation testing. A negative panel that omitted COX20 does not exclude it.

DNA Sequencing NCIT:C153598

Show evidence (3 references)

PMID:35651336 SUPPORT Human Clinical

"Exome sequencing revealed two compound heterozygous variants of the COX20 gene (c.222G > T and c.41A > G) that co-segregated with the disorder in both patients."

Exome analysis and family segregation established the molecular diagnosis.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1224/ SUPPORT REVIEW SYNTHESIS Other

"Molecular genetic testing is used to establish the diagnosis."

General mitochondrial guidance supports molecular confirmation.

PMID:41010014 SUPPORT Human Clinical

"a gene panel for hereditary neuropathies, which did not include the COX20 gene, revealed no significant findings."

The negative earlier panel had a gene-content limitation.

Nerve-conduction studies

Assess sensory amplitudes and distribution alongside motor conduction. Sensory studies may be normal early, so repeat testing is appropriate when the clinical syndrome progresses.

Nerve Conduction Velocity Test NCIT:C88502

Show evidence (2 references)

PMID:37095481 SUPPORT Human Clinical

"At the age of 4.5, the patient underwent magnetic resonance imaging (MRI) and nerve conduction tests, but all the results were normal."

The initial study was normal.

PMID:37095481 SUPPORT Human Clinical

"However, the examination of nerve conduction performed on him again revealed severe axonal sensory neuropathy."

Repeat testing at age five demonstrated the evolving sensory neuropathy.

Brain and spinal MRI

Assess cerebellar, cerebral and spinal changes when indicated. Cord atrophy may coexist with normal cerebellar imaging, and entirely normal MRI does not exclude the disorder.

Magnetic Resonance Imaging NCIT:C16809

Show evidence (3 references)

PMID:41010014 SUPPORT Human Clinical

"Cerebellar atrophy was absent on all imaging studies"

The adult case had normal cerebellar structure despite cord atrophy.

PMID:41010014 SUPPORT Human Clinical

"Spinal cord MRI performed at the age of 20 years demonstrated cervical and thoracic cord atrophy"

Both cord regions were involved.

PMID:37095481 SUPPORT Human Clinical

"An MRI of his brain and spine showed a normal result."

The child had genetically confirmed disease despite normal imaging.

Lactate testing

Lactate can be elevated but is often normal. A normal concentration does not exclude mitochondrial disease or COX20 deficiency.

Lactic Acid Measurement NCIT:C79450

Show evidence (2 references)

url:https://oup.silverchair-cdn.com/article-minimal/6711551 SUPPORT REVIEW SYNTHESIS Human Clinical

"Standard laboratory analyses detected mildly elevated serum lactate levels in 4/17 of patients (23.5%)"

Only a minority of tested cases in the literature compilation had elevated lactate.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1224/ SUPPORT REVIEW SYNTHESIS Other

"Normal plasma or CSF lactic acid concentration does not exclude the presence of a mitochondrial disorder."

GeneReviews explicitly cautions against exclusion on a normal lactate result.

Tissue and cellular functional studies

Respiratory-chain enzymology, COX histochemistry, immunoblotting, blue-native electrophoresis and RNA studies can support variant interpretation. Sensitivity differs by assay, tissue and genotype; normal fibroblast OXPHOS does not negate a molecular diagnosis.

Respiratory-chain enzymology and complex IV assembly analysis

The composite combines enzyme assays, protein-complex analysis and RNA studies. NCIT search 'l~Enzyme Activity' returns the activity concept NCIT:C180567, which is not a diagnostic procedure; it is not substituted for this combination.

Show evidence (3 references)

url:https://oup.silverchair-cdn.com/article-minimal/6711551 SUPPORT REVIEW SYNTHESIS Human Clinical

"an isolated complex IV defect in the skeletal muscle of two patients"

The literature review describes reduced complex IV activity in patient muscle tissue.

PMID:23125284 SUPPORT In Vitro

"Cells affected by the mutation accumulate subassemblies of complex IV that contain COX1 but are almost devoid of COX2 protein."

Patient-fibroblast subassemblies demonstrate failed incorporation of COX2.

url:https://oup.silverchair-cdn.com/article-minimal/6711551 REFUTE REVIEW SYNTHESIS In Vitro

"normal OXPHOS activity in the fibroblasts of three patients"

These cultured-fibroblast results refute universal assay-detectable deficiency. Together with reduced activity in other tissues and lines they support the Variable presence annotation, not reduced activity in these three cultures.

Prenatal familial-variant testing

After defining familial variants, prenatal testing can determine fetal genotype. Amniocentesis identified an affected fetus and chorionic-villus testing in a later pregnancy identified a heterozygous carrier in one reported family. Testing and reproductive decisions require nondirective counseling.

Prenatal molecular testing of familial COX20 variants NCIT:C15709

Show evidence (2 references)

PMID:39897410 SUPPORT Human Clinical

"the mother of the patient underwent amniocentesis during a subsequent pregnancy. The procedure confirmed that the fetus carried identical mutations in the COX20 gene as the proband."

A family received prenatal molecular testing.

PMID:39897410 SUPPORT Human Clinical

"WES detected only the heterozygous mutation c.41A>G (p.Lys14Arg), consistent with the maternal genotype."

A subsequent chorionic-villus sample was heterozygous, followed by birth of an unaffected child.

📊

Related Datasets

2

Illumina Genome Analyzer II sequencing: Exo-Seq of blood SRA:SRR18749879

Public sequencing run linked by Li et al. to the COX20 ophthalmoplegia/visual-failure family. The paper reports these two run accessions; individual sample assignment is not inferred.

WES

PMID:35651336

ENA experiment title is reproduced verbatim. ENA labels the library strategy WGS, whereas its experiment title and the associated paper describe exome sequencing; WES follows the publication.

Illumina Genome Analyzer II sequencing: Exo-Seq of blood SRA:SRR18749880

Public sequencing run linked by Li et al. to the COX20 ophthalmoplegia/visual-failure family. The paper reports these two run accessions; individual sample assignment is not inferred.

WES

PMID:35651336

ENA experiment title is reproduced verbatim. ENA labels the library strategy WGS, whereas its experiment title and the associated paper describe exome sequencing; WES follows the publication.

🧫

Experimental Models

4

COX20-depleted HEK293T cells CELL_LINE

siRNA and TALEN-based COX20 depletion demonstrate rapid COX2 turnover, assembly intermediates and residual complex IV activity. COX20-FLAG permits rescue and interaction studies.

Pathograph links

COX2 Instability recapitulates fidelity: moderate observes: cellular Pulse-chase analysis shows rapid COX2 turnover.

Limitations: Culture findings do not establish clinical treatment efficacy or the full neurological phenotype.

Show evidence (1 reference)

PMID:24403053 SUPPORT In Vitro

"newly synthesized COX2 is unstable and most of it is rapidly degraded within 2 h of the chase"

Pulse-chase analysis in COX20-silenced cells identifies reduced COX2 stability rather than a primary synthesis defect.

Reduced Complex IV Assembly recapitulates fidelity: moderate observes: cellular Engineered cells accumulate assembly intermediates.

Limitations: Culture findings do not establish clinical treatment efficacy or the full neurological phenotype.

Show evidence (1 reference)

PMID:24403053 SUPPORT In Vitro

"Mitochondria lacking COX20 accumulate CIV subassemblies containing COX1 and COX4"

The engineered human-cell system reproduces the assembly lesion.

Show evidence (2 references)

PMID:24403053 SUPPORT In Vitro

"newly synthesized COX2 is unstable and most of it is rapidly degraded within 2 h of the chase"

Pulse-chase analysis in COX20-silenced cells identifies reduced COX2 stability rather than a primary synthesis defect.

PMID:24403053 SUPPORT INDIRECT In Vitro

"We propose that COX20 acts as a chaperone in the early steps of COX2 maturation, stabilizing the newly synthesized protein and presenting COX2 to its metallochaperone module"

Protein-interaction experiments motivate the COX2 presentation model; direct copper transport by COX20 is not established.

Patient fibroblast complementation PRIMARY_CELL_CULTURE

Patient fibroblasts support RNA, protein, assembly and respiratory analyses. Wild-type lentiviral or adenoviral COX20 restores cellular function in reported lines; other patients can have normal routine enzyme assays.

Pathograph links

Reduced Complex IV Assembly rescues fidelity: moderate observes: cellular Wild-type COX20 increases assembled complex IV.

Limitations: Culture findings do not establish clinical treatment efficacy or the full neurological phenotype.

Show evidence (1 reference)

PMID:23125284 SUPPORT In Vitro

"Lentiviral complementation of patient's fibroblasts with wild-type FAM36A increases the complex IV activity as well as the amount of holocomplex IV and of individual subunits."

Genetic complementation supports COX20 causality in culture.

Reduced Respiratory Reserve rescues fidelity: moderate observes: cellular Adenoviral COX20 partially restores mitochondrial function.

Limitations: Culture findings do not establish clinical treatment efficacy or the full neurological phenotype.

Show evidence (1 reference)

PMID:35651336 SUPPORT In Vitro

"Overexpression of COX20 using a transduced adenovirus partially restored the function of the patients' fibroblasts."

This is cell complementation, not a clinical gene-therapy trial.

Show evidence (3 references)

PMID:30656193 SUPPORT In Vitro

"Consistent with this finding, protein analysis revealed no detectable COX20 protein present"

Immunoblotting of patient fibroblasts demonstrates loss of detectable COX20.

PMID:23125284 SUPPORT In Vitro

"Lentiviral complementation of patient's fibroblasts with wild-type FAM36A increases the complex IV activity as well as the amount of holocomplex IV and of individual subunits."

Genetic complementation supports COX20 causality in culture.

PMID:35651336 SUPPORT In Vitro

"Overexpression of COX20 using a transduced adenovirus partially restored the function of the patients' fibroblasts."

This is cell complementation, not a clinical gene-therapy trial.

COX20-silenced ND7/23 cells CELL_LINE

Two lentiviral-shRNA knockdown clones model respiratory and stress phenotypes in a sensory-neuron-like line. The stronger clone shows the clearer assembled-complex-IV and peroxide-viability abnormalities.

Pathograph links

Reduced Respiratory Reserve recapitulates fidelity: moderate observes: cellular Knockdown reduces ATP-linked respiration and reserve.

Limitations: Culture findings do not establish clinical treatment efficacy or the full neurological phenotype.

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6180070 SUPPORT In Vitro

"knockdown of COX20 expression resulted in the reduction of ATP-linked OCR and maximal respiration OCR, indicating a lower spare respiratory capacity."

Respirometry demonstrates reduced ATP-linked respiration and reserve in ND7/23 cultures; it does not establish total ATP collapse.

Reduced Cellular Stress Tolerance recapitulates fidelity: moderate observes: cellular Galactose challenge accentuates the growth defect.

Limitations: Culture findings do not establish clinical treatment efficacy or the full neurological phenotype.

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6180070 SUPPORT In Vitro

"growth rate was significantly lower in siCOX20 cells than that in control cells in regular glucose medium, and further decreased in oxidative phosphorylation-promoting galactose media."

COX20 silencing impairs cultured-cell growth, particularly when oxidative phosphorylation is required.

Show evidence (2 references)

url:https://oup.silverchair-cdn.com/article-minimal/6180070 SUPPORT In Vitro

"knockdown of COX20 expression resulted in the reduction of ATP-linked OCR and maximal respiration OCR, indicating a lower spare respiratory capacity."

Respirometry demonstrates reduced ATP-linked respiration and reserve in ND7/23 cultures; it does not establish total ATP collapse.

url:https://oup.silverchair-cdn.com/article-minimal/6180070 SUPPORT In Vitro

"growth rate was significantly lower in siCOX20 cells than that in control cells in regular glucose medium, and further decreased in oxidative phosphorylation-promoting galactose media."

COX20 silencing impairs cultured-cell growth, particularly when oxidative phosphorylation is required.

COX20 splice and protein-stability assays CELL_LINE

Minigene analysis supports c.157+7A>G-associated exon-2 skipping; tagged-protein expression and cycloheximide chase distinguish S33L/W74C protein instability from the c.41A>G splice defect. Proteasome inhibition in these assays is not an established treatment.

Pathograph links

COX20 Protein Instability recapitulates fidelity: moderate observes: cellular Mutant constructs turn over faster than wild type.

Limitations: Culture findings do not establish clinical treatment efficacy or the full neurological phenotype.

Show evidence (1 reference)

url:https://oup.silverchair-cdn.com/article-minimal/6180070 SUPPORT In Vitro

"mutant COX20, especially W74C-COX20, were degraded faster than wild-type, suggesting that the two missense variants affected the protein half-life of COX20."

Cycloheximide-chase experiments support instability of S33L and W74C proteins.

Show evidence (2 references)

url:https://oup.silverchair-cdn.com/article-minimal/6180070 SUPPORT In Vitro

"mutant COX20, especially W74C-COX20, were degraded faster than wild-type, suggesting that the two missense variants affected the protein half-life of COX20."

Cycloheximide-chase experiments support instability of S33L and W74C proteins.

url:https://oup.silverchair-cdn.com/article-minimal/6180070 SUPPORT In Vitro

"We found that MG132 treatment rescued the degradation of already synthesized mutant proteins, particularly in S33L-COX20"

The proteasome experiment addresses mutant-protein turnover in transfected cells.

🐁

Animal Models

1

Saccharomyces cerevisiae cox20 deletion

The deletion produces a respiratory-growth defect rescued by native yeast Cox20 but not human COX20 despite mitochondrial import. Yeast Cox2 has a cleaved N-terminal precursor absent from human COX2, limiting direct functional interchangeability.

Species

Saccharomyces cerevisiae

Genotype

cox20 deletion

Pathograph links

Reduced Complex IV Activity recapitulates fidelity: moderate observes: cellular The model reproduces impaired respiratory function associated with Cox20 loss.

Limitations: Yeast precursor processing differs from human COX2 maturation, and the model does not reproduce neurological disease.

Show evidence (1 reference)

PMID:24403053 SUPPORT Model Organism

"ScCox20-HA complemented the respiratory defect of Δcox20 yeast, but the human protein did not"

Native yeast complementation supports the conserved respiratory role; lack of cross-species complementation limits extrapolation.

Show evidence (1 reference)

PMID:24403053 SUPPORT Model Organism

"ScCox20-HA complemented the respiratory defect of Δcox20 yeast, but the human protein did not"

Native yeast complementation supports the conserved respiratory role; lack of cross-species complementation limits extrapolation.

{ }

Source YAML

click to show

name: COX20-Related COX Deficiency
category: Mendelian
creation_date: '2026-06-15T00:00:00Z'
synonyms:
- COX20 deficiency
- FAM36A deficiency
- Mitochondrial complex IV deficiency, nuclear type 11
- MC4DN11
- COX20-related cytochrome c oxidase deficiency
description: COX20-related mitochondrial complex IV deficiency is an autosomal recessive disorder caused by biallelic COX20 (FAM36A) variants. COX20 stabilizes newly synthesized COX2 and supports its maturation and incorporation into complex IV. Splice defects and protein-destabilizing variants reduce functional COX20. The clinical spectrum includes infantile hypotonia, childhood-onset sensory-predominant neuropathy, sensory or cerebellar ataxia, dysarthria, dystonia, and variable visual, motor and cognitive involvement. Progression can cause loss of independent walking, although severity and tempo vary. Normal lactate, brain MRI, early nerve-conduction studies or fibroblast respiratory assays do not exclude the disorder.
disease_term:
  preferred_term: COX20-related COX deficiency (MC4DN11)
  term:
    id: MONDO:0033645
    label: mitochondrial complex IV deficiency, nuclear type 11
parents:
- Mitochondrial Disease
- Inborn Error of Metabolism
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    notes: Mendelian, autosomal recessive nuclear-gene mitochondrial disorder; Harrison's covers primary mitochondrial disease under the genetics/environment Part.
  - classification_value: ENDOCRINOLOGY_METABOLISM
    notes: An inborn error of mitochondrial energy metabolism involving complex IV assembly.
  - classification_value: NEUROLOGIC
    notes: The clinical spectrum prominently involves sensory neuropathy, ataxia and movement disorders.
  mechanistic_category:
  - classification_value: mitochondrial disease
    notes: Nuclear-encoded defect of mitochondrial respiratory chain Complex IV biogenesis; a primary mitochondrial disease.
  icimd_category:
  - classification_value: complex_iv_subunits_and_assembly_factors
    notes: 'ICIMD (Ferreira et al. 2021, PMID:33340416): group "Nuclear-encoded complex IV subunit and assembly factor defects" under category "Disorders of nuclear-encoded oxidative phosphorylation". COX20/FAM36A is a nuclear-encoded inner-membrane chaperone required for COX2 maturation.'
pathophysiology:
- name: Aberrant COX20 Splicing
  description: Variants at or near splice donors reduce productive COX20 transcripts. The recurrent c.41A>G coding-position variant removes 20 bases from exon 1; c.157+3G>C promotes an exon-2-skipped noncoding transcript.
  evidence:
  - reference: PMID:35651336
    reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: TA clone sequencing demonstrated that aligned with the reference sequence (NM_198076.6), the c.41A > G mutation led to a 20 bp deletion in exon 1.
    explanation: Patient-fibroblast transcript sequencing demonstrates the splice effect of the coding-position variant.
  - reference: PMID:30656193
    reference_title: Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: One variant (IVS2+3G>C), located near intron-2’s splice donor site, resulted in increased expression of the ΔEXON2 mRNA.
    explanation: Patient RNA analysis identifies a distinct exon-2 splicing defect.
  biological_scale: MOLECULAR
  genes:
  - preferred_term: COX20
    term:
      id: hgnc:26970
      label: COX20
  downstream:
  - target: COX20 Protein Deficiency
    description: Loss of productive transcript reduces COX20 abundance.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30656193
      reference_title: Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Consistent with this finding, protein analysis revealed no detectable COX20 protein present
      explanation: Immunoblotting of patient fibroblasts demonstrates loss of detectable COX20.
- name: COX20 Protein Instability
  description: S33L and W74C substitutions accelerate COX20 turnover in transfected cells. Mutant proteins retain mitochondrial inner-membrane localization.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: mutant COX20, especially W74C-COX20, were degraded faster than wild-type, suggesting that the two missense variants affected the protein half-life of COX20.
    explanation: Cycloheximide-chase experiments support instability of S33L and W74C proteins.
  biological_scale: MOLECULAR
  genes:
  - preferred_term: COX20
    term:
      id: hgnc:26970
      label: COX20
  downstream:
  - target: COX20 Protein Deficiency
    description: Accelerated turnover reduces steady-state COX20 abundance.
    causal_link_type: DIRECT
    evidence:
    - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
      reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: mutant COX20, especially W74C-COX20, were degraded faster than wild-type, suggesting that the two missense variants affected the protein half-life of COX20.
      explanation: Cycloheximide-chase experiments support instability of S33L and W74C proteins.
- name: COX20 Protein Deficiency
  description: Loss of functional COX20 removes a COX2-specific chaperone and assembly adaptor. Patient fibroblasts can have nearly absent protein despite normal routine respiratory-enzyme assays.
  evidence:
  - reference: PMID:30656193
    reference_title: Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Consistent with this finding, protein analysis revealed no detectable COX20 protein present
    explanation: Immunoblotting of patient fibroblasts demonstrates loss of detectable COX20.
  - reference: PMID:24403053
    reference_title: Human COX20 cooperates with SCO1 and SCO2 to mature COX2 and promote the assembly of cytochrome c oxidase.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We propose that COX20 acts as a chaperone in the early steps of COX2 maturation, stabilizing the newly synthesized protein and presenting COX2 to its metallochaperone module
    explanation: Protein-interaction experiments motivate the COX2 presentation model; direct copper transport by COX20 is not established.
    directness: INDIRECT
  - reference: PMID:31079202
    reference_title: Observation of novel COX20 mutations related to autosomal recessive axonal neuropathy and static encephalopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: decreased COX20 protein level of peripheral blood leucocytes derived from the patients
    explanation: Reduced protein in patient-derived blood leucocytes provides uncultured human-tissue evidence, complementing the fibroblast experiments.
  biological_scale: MOLECULAR
  genes:
  - preferred_term: COX20
    term:
      id: hgnc:26970
      label: COX20
  molecular_functions:
  - preferred_term: COX20-dependent presentation of COX2 to maturation partners
    term:
      id: GO:0030674
      label: protein-macromolecule adaptor activity
    modifier: DECREASED
    description: The adaptor annotation represents coordination of COX2 with its maturation partners, rather than ATP-dependent folding or copper transport.
  downstream:
  - target: COX2 Instability
    description: Loss of COX20 destabilizes newly synthesized COX2 in engineered human cells.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24403053
      reference_title: Human COX20 cooperates with SCO1 and SCO2 to mature COX2 and promote the assembly of cytochrome c oxidase.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: newly synthesized COX2 is unstable and most of it is rapidly degraded within 2 h of the chase
      explanation: Pulse-chase analysis in COX20-silenced cells identifies reduced COX2 stability rather than a primary synthesis defect.
  - target: Impaired COX2 Maturation
    description: Loss of the chaperone limits presentation of COX2 to its metallochaperone machinery.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:24403053
      reference_title: Human COX20 cooperates with SCO1 and SCO2 to mature COX2 and promote the assembly of cytochrome c oxidase.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: We propose that COX20 acts as a chaperone in the early steps of COX2 maturation, stabilizing the newly synthesized protein and presenting COX2 to its metallochaperone module
      explanation: Protein-interaction experiments motivate the COX2 presentation model; direct copper transport by COX20 is not established.
      directness: INDIRECT
- name: COX2 Instability
  description: 'Newly synthesized COX2 turns over rapidly in COX20-depleted HEK293T cells. This model result is not uniform across patient cultures: two 2021 patient lines retained normal steady-state COX2.'
  evidence:
  - reference: PMID:24403053
    reference_title: Human COX20 cooperates with SCO1 and SCO2 to mature COX2 and promote the assembly of cytochrome c oxidase.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: newly synthesized COX2 is unstable and most of it is rapidly degraded within 2 h of the chase
    explanation: Pulse-chase analysis in COX20-silenced cells identifies reduced COX2 stability rather than a primary synthesis defect.
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
    supports: REFUTE
    evidence_source: IN_VITRO
    snippet: Western blot analysis revealed COX2 protein was not affected in the fibroblasts of Patients 1 and 5.
    explanation: The patient lines refute a universal reduction in steady-state COX2.
  biological_scale: MOLECULAR
  downstream:
  - target: Reduced Complex IV Assembly
    description: Reduced stable COX2 limits incorporation into the holoenzyme.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:23125284
      reference_title: A mutation in the FAM36A gene, the human ortholog of COX20, impairs cytochrome c oxidase assembly and is associated with ataxia and muscle hypotonia.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Cells affected by the mutation accumulate subassemblies of complex IV that contain COX1 but are almost devoid of COX2 protein.
      explanation: Patient-fibroblast subassemblies demonstrate failed incorporation of COX2.
- name: Impaired COX2 Maturation
  description: COX20-bound COX2 interacts with SCO1/SCO2 during maturation. Co-immunoprecipitation supports coordination of this machinery; it does not prove direct COX20-SCO binding or quantify copper loading.
  evidence:
  - reference: PMID:24403053
    reference_title: Human COX20 cooperates with SCO1 and SCO2 to mature COX2 and promote the assembly of cytochrome c oxidase.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We propose that COX20 acts as a chaperone in the early steps of COX2 maturation, stabilizing the newly synthesized protein and presenting COX2 to its metallochaperone module
    explanation: Protein-interaction experiments motivate the COX2 presentation model; direct copper transport by COX20 is not established.
    directness: INDIRECT
  biological_scale: MOLECULAR
  downstream:
  - target: Reduced Complex IV Assembly
    description: Failure to supply mature COX2 limits complex IV biogenesis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:23125284
      reference_title: A mutation in the FAM36A gene, the human ortholog of COX20, impairs cytochrome c oxidase assembly and is associated with ataxia and muscle hypotonia.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Cells affected by the mutation accumulate subassemblies of complex IV that contain COX1 but are almost devoid of COX2 protein.
      explanation: Patient-fibroblast subassemblies demonstrate failed incorporation of COX2.
- name: Reduced Complex IV Assembly
  description: COX1-containing intermediates accumulate and the mature complex IV pool decreases when COX2 incorporation is impaired.
  evidence:
  - reference: PMID:23125284
    reference_title: A mutation in the FAM36A gene, the human ortholog of COX20, impairs cytochrome c oxidase assembly and is associated with ataxia and muscle hypotonia.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Cells affected by the mutation accumulate subassemblies of complex IV that contain COX1 but are almost devoid of COX2 protein.
    explanation: Patient-fibroblast subassemblies demonstrate failed incorporation of COX2.
  - reference: PMID:35651336
    reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: These findings demonstrate that COX20 variants led to a specific reduction of CIV levels and very low residual levels of fully assembled CIV
    explanation: Blue-native electrophoresis establishes reduced assembled complex IV in patient fibroblasts.
  biological_scale: MOLECULAR
  conforms_to: complex_iv_assembly_deficiency#Complex IV Biogenesis Failure
  genes:
  - preferred_term: COX20
    term:
      id: hgnc:26970
      label: COX20
  biological_processes:
  - preferred_term: mitochondrial respiratory chain complex IV assembly
    term:
      id: GO:0033617
      label: mitochondrial respiratory chain complex IV assembly
    modifier: DECREASED
  downstream:
  - target: Reduced Complex IV Activity
    description: The reduction in assembled enzyme limits terminal respiratory-chain activity.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35651336
      reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: The enzyme activities of complex IV were lower in the patient's cells than in control cells
      explanation: Patient-fibroblast enzyme assays establish reduced complex IV activity.
- name: Reduced Complex IV Activity
  description: Complex IV enzyme activity is reduced in patient fibroblasts and engineered cells. Residual activity, tissue dependence and occasional additional complex abnormalities preclude a universal complete or strictly isolated deficiency.
  evidence:
  - reference: PMID:35651336
    reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The enzyme activities of complex IV were lower in the patient's cells than in control cells
    explanation: Patient-fibroblast enzyme assays establish reduced complex IV activity.
  biological_scale: MOLECULAR
  biological_processes:
  - preferred_term: mitochondrial electron transport, cytochrome c to oxygen
    term:
      id: GO:0006123
      label: mitochondrial electron transport, cytochrome c to oxygen
    modifier: DECREASED
  downstream:
  - target: Reduced Respiratory Reserve
    description: Reduced terminal electron transport constrains oxidative respiratory capacity.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
      reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: knockdown of COX20 expression resulted in the reduction of ATP-linked OCR and maximal respiration OCR, indicating a lower spare respiratory capacity.
      explanation: Respirometry demonstrates reduced ATP-linked respiration and reserve in ND7/23 cultures; it does not establish total ATP collapse.
- name: Reduced Respiratory Reserve
  description: COX20-silenced sensory-neuron-like cells show reduced ATP-linked respiration, maximal respiration and spare capacity. Patient fibroblasts also show impaired oxidative phosphorylation.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: knockdown of COX20 expression resulted in the reduction of ATP-linked OCR and maximal respiration OCR, indicating a lower spare respiratory capacity.
    explanation: Respirometry demonstrates reduced ATP-linked respiration and reserve in ND7/23 cultures; it does not establish total ATP collapse.
  - reference: PMID:35651336
    reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Basal respiration, maximal respiration, ATP production, and spare respiratory capacity of fibroblasts from the patient are significantly lower than those of control.
    explanation: The independent patient-fibroblast study confirms bioenergetic impairment.
  biological_scale: CELLULAR
  biological_processes:
  - preferred_term: mitochondrial ATP synthesis coupled electron transport
    term:
      id: GO:0042775
      label: mitochondrial ATP synthesis coupled electron transport
    modifier: DECREASED
  downstream:
  - target: Reduced Cellular Stress Tolerance
    description: Reduced energetic reserve accompanies impaired growth under metabolic challenge.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
      reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: growth rate was significantly lower in siCOX20 cells than that in control cells in regular glucose medium, and further decreased in oxidative phosphorylation-promoting galactose media.
      explanation: COX20 silencing impairs cultured-cell growth, particularly when oxidative phosphorylation is required.
  - target: Neurological Dysfunction
    description: Cellular bioenergetic defects are a plausible basis of the clinical neurological syndrome; tissue-specific intermediate steps remain incompletely resolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33751098
      reference_title: Bi-allelic loss of function variants in COX20 gene cause autosomal recessive sensory neuronopathy.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: loss of COX20 contributing to mitochondrial bioenergetic dysfunction as a mechanism in peripheral sensory neuron disease
      explanation: The authors integrate cell experiments with clinical sensory neuronopathy; this is an inferred bridge.
      directness: INDIRECT
- name: Reduced Cellular Stress Tolerance
  description: Knockdown reduces ND7/23 proliferation under galactose challenge and, in the stronger knockdown clone, viability after peroxide exposure. These culture experiments do not directly demonstrate neuronal death in patients.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: growth rate was significantly lower in siCOX20 cells than that in control cells in regular glucose medium, and further decreased in oxidative phosphorylation-promoting galactose media.
    explanation: COX20 silencing impairs cultured-cell growth, particularly when oxidative phosphorylation is required.
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: significantly suppressed the cell viability in siCOX20-2 cells
    explanation: Hydrogen peroxide exposure reduced viability in the stronger knockdown clone.
  biological_scale: CELLULAR
  downstream:
  - target: Neurological Dysfunction
    description: Reduced cellular resilience could contribute to progressive neural dysfunction; the in-vivo connection remains an inference.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Neurological Dysfunction
  description: Central and peripheral neurological involvement varies across patients, including sensory neuronopathy, movement abnormalities, motor impairment and cognitive symptoms. The intervening tissue-specific consequences of respiratory dysfunction are incompletely defined.
  evidence:
  - reference: PMID:41010014
    reference_title: Mitochondrial Complex IV Deficiency Nuclear Type 11 Caused by a Novel Start-Lost Variant in the COX20 Gene.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The patient exhibited progressive ataxia, pyramidal signs, and peripheral neuropathy, accompanied by cervical spinal cord atrophy
    explanation: The adult case documents combined central and peripheral involvement.
  biological_scale: ORGANISM
  downstream:
  - target: Large Sensory Fiber Loss
    description: Peripheral neural involvement includes loss of large myelinated fibers.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35651336
      reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Pronounced depletion of large myelinated fibers by approximately 80% in the MGT-stained sural nerve
      explanation: The proband biopsy documents large-fiber loss; this does not by itself establish primary demyelination.
  - target: Hypotonia
    description: The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Ataxia
    description: The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Dysarthria
    description: The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Dystonia
    description: The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Limb Weakness
    description: The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Motor Delay
    description: The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Intellectual Disability
    description: The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Spasticity
    description: The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Visual Impairment
    description: The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: External Ophthalmoplegia
    description: The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Cerebellar Atrophy
    description: The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Cervical Spinal Cord Atrophy
    description: The clinical syndrome includes this manifestation; the specific intermediate mechanism is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Cerebral Atrophy
    description: Central involvement can include structural cerebral loss; the cellular intermediates remain unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Static Encephalopathy
    description: Central dysfunction can present as static encephalopathy; specific intervening tissue mechanisms are not established.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:31079202
      reference_title: Observation of novel COX20 mutations related to autosomal recessive axonal neuropathy and static encephalopathy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: two patients from a non-consanguineous family exhibiting autosomal recessive sensory-dominant axonal neuropathy and static encephalopathy
      explanation: Xu et al. describe static encephalopathy in two siblings; this is distinct from progressive gait impairment or a generic intellectual-disability label.
- name: Large Sensory Fiber Loss
  description: Sural nerve pathology shows depletion of large myelinated fibers. Non-length-dependent sensory potentials and proprioceptive loss support a sensory neuronopathy in a subset, although direct dorsal-root-ganglion pathology has not been demonstrated in these patients.
  evidence:
  - reference: PMID:35651336
    reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Pronounced depletion of large myelinated fibers by approximately 80% in the MGT-stained sural nerve
    explanation: The proband biopsy documents large-fiber loss; this does not by itself establish primary demyelination.
  - reference: PMID:33751098
    reference_title: Bi-allelic loss of function variants in COX20 gene cause autosomal recessive sensory neuronopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All patients displayed sensory ataxia with a decrease in non-length-dependent sensory potentials.
    explanation: The eight-family cohort establishes sensory neuronopathy, with ascertainment focused on that presentation.
  biological_scale: TISSUE
  cell_types:
  - preferred_term: sensory neuron
    term:
      id: CL:0000101
      label: sensory neuron
  downstream:
  - target: Sensory Axonal Neuropathy
    description: Large-fiber loss accompanies severe sensory nerve-conduction abnormalities.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33751098
      reference_title: Bi-allelic loss of function variants in COX20 gene cause autosomal recessive sensory neuronopathy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: All patients displayed sensory ataxia with a decrease in non-length-dependent sensory potentials.
      explanation: The eight-family cohort establishes sensory neuronopathy, with ascertainment focused on that presentation.
  - target: Impaired Proprioception
    description: Large sensory-fiber dysfunction impairs position sense.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Impaired Vibration Sense
    description: Large sensory-fiber dysfunction impairs vibration sense.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Areflexia
    description: Loss of sensory input can impair the reflex arc.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
phenotypes:
- name: Hypotonia
  category: Neurologic
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  description: May begin in infancy or childhood; some patients later develop increased tone.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most frequent clinical features are neuropathy (24/27), ataxia (20/27), dysarthria (16/27), hypotonia (10/27), dystonia (6/27) and ophthalmoplegia (6/27).
    explanation: These are descriptive counts in the 27-case literature compilation, not population frequencies.
    quote_role: REVIEW_SYNTHESIS
  phenotype_contexts:
  - subtype: Infantile hypotonia presentation
    notes: Early hypotonia defines this proposed presentation; this does not restrict hypotonia to it.
    evidence:
    - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
      reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Only 3/27 patients (11.4%) presented with infantile hypotonia immediately after birth.
      explanation: The 2022 authors characterize this descriptive clinical presentation.
      quote_role: REVIEW_SYNTHESIS
- name: Ataxia
  category: Neurologic
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  description: Sensory and cerebellar presentations both occur. Gait deterioration can precede demonstrable neuropathy.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most frequent clinical features are neuropathy (24/27), ataxia (20/27), dysarthria (16/27), hypotonia (10/27), dystonia (6/27) and ophthalmoplegia (6/27).
    explanation: These are descriptive counts in the 27-case literature compilation, not population frequencies.
    quote_role: REVIEW_SYNTHESIS
- name: Dysarthria
  category: Neurologic
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  description: Often progressive childhood-onset speech impairment.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most frequent clinical features are neuropathy (24/27), ataxia (20/27), dysarthria (16/27), hypotonia (10/27), dystonia (6/27) and ophthalmoplegia (6/27).
    explanation: These are descriptive counts in the 27-case literature compilation, not population frequencies.
    quote_role: REVIEW_SYNTHESIS
- name: Dystonia
  category: Neurologic
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  description: May emerge after early gait symptoms; it was present in the older three, not all four, Otero subjects.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most frequent clinical features are neuropathy (24/27), ataxia (20/27), dysarthria (16/27), hypotonia (10/27), dystonia (6/27) and ophthalmoplegia (6/27).
    explanation: These are descriptive counts in the 27-case literature compilation, not population frequencies.
    quote_role: REVIEW_SYNTHESIS
  phenotype_contexts:
  - subtype: Neuropathy and dystonia-ataxia overlap
    notes: This proposed overlap cluster had later dystonia; the medians describe the reported cases, not individual prognosis.
    evidence:
    - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
      reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: this subgroup had a later age of onset, starting with neuropathy (median 7 years), dystonia (median 12 years) and dysarthria (median 13 years).
      explanation: The 2022 authors characterize this descriptive clinical presentation.
      quote_role: REVIEW_SYNTHESIS
- name: External Ophthalmoplegia
  category: Ophthalmologic
  phenotype_term:
    preferred_term: External ophthalmoplegia
    term:
      id: HP:0000544
      label: External ophthalmoplegia
  description: Eye-movement impairment occurs in part of the clinical spectrum and is not universal.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most frequent clinical features are neuropathy (24/27), ataxia (20/27), dysarthria (16/27), hypotonia (10/27), dystonia (6/27) and ophthalmoplegia (6/27).
    explanation: These are descriptive counts in the 27-case literature compilation, not population frequencies.
    quote_role: REVIEW_SYNTHESIS
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1224/
    reference_title: Primary Mitochondrial Disorders Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Common clinical features of mitochondrial disorders include ptosis, external ophthalmoplegia, proximal myopathy and exercise intolerance
    explanation: General mitochondrial context, not a COX20-specific frequency estimate.
    quote_role: BACKGROUND
- name: Sensory Axonal Neuropathy
  category: Neurologic
  phenotype_term:
    preferred_term: Sensory axonal neuropathy
    term:
      id: HP:0003390
      label: Sensory axonal neuropathy
  description: Sensory nerve action potentials can be severely reduced or absent despite limited subjective sensory symptoms. Motor involvement ranges from absent to sensorimotor axonal or mixed abnormalities.
  evidence:
  - reference: PMID:33751098
    reference_title: Bi-allelic loss of function variants in COX20 gene cause autosomal recessive sensory neuronopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All patients displayed sensory ataxia with a decrease in non-length-dependent sensory potentials.
    explanation: The eight-family cohort establishes sensory neuronopathy, with ascertainment focused on that presentation.
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 8/19 had normal/decreased motor conduction velocities (MCV) plus low CMAP amplitude, compatible with mixed sensorimotor axonal neuropathy.
    explanation: Motor involvement in the pooled literature prevents treating COX20 disease as invariably pure sensory neuropathy.
    quote_role: REVIEW_SYNTHESIS
  sequelae:
  - target: Ataxia
    description: Loss of sensory feedback contributes to the sensory component of ataxia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33751098
      reference_title: Bi-allelic loss of function variants in COX20 gene cause autosomal recessive sensory neuronopathy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: All patients displayed sensory ataxia with a decrease in non-length-dependent sensory potentials.
      explanation: The eight-family cohort establishes sensory neuronopathy, with ascertainment focused on that presentation.
  phenotype_contexts:
  - subtype: Childhood axonal neuropathy presentation
    notes: The proposed neuropathy presentation includes both sensory-only and sensorimotor findings.
    evidence:
    - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
      reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: patients in this phenotypical subgroup had severe axonal neuropathy (15/20 mixed motor sensory neuropathy and 5/20 pure sensory neuropathy)
      explanation: The 2022 authors characterize this descriptive clinical presentation.
      quote_role: REVIEW_SYNTHESIS
- name: Areflexia
  category: Neurologic
  phenotype_term:
    preferred_term: Areflexia
    term:
      id: HP:0001284
      label: Areflexia
  description: Absent reflexes are common in neuropathic presentations; brisk reflexes can occur with central involvement.
  evidence:
  - reference: PMID:37095481
    reference_title: 'Clinical and genetic characteristics of children with COX20-associated mitochondrial disorder: case report and literature review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A neurological examination performed on him, revealed hypotonia, Romberg sign, and the absence of deep tendon reflexes.
    explanation: The child had absent deep tendon reflexes.
- name: Impaired Proprioception
  category: Neurologic
  phenotype_term:
    preferred_term: Impaired proprioception
    term:
      id: HP:0010831
      label: Impaired proprioception
  description: Deep sensory loss contributes to sensory ataxia.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: early-onset progressive sensory ataxia, loss of position and vibration sense, absent tendon reflexes
    explanation: The cohort phenotype includes loss of position and vibration sense.
  sequelae:
  - target: Ataxia
    description: Loss of sensory feedback contributes to the sensory component of ataxia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33751098
      reference_title: Bi-allelic loss of function variants in COX20 gene cause autosomal recessive sensory neuronopathy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: All patients displayed sensory ataxia with a decrease in non-length-dependent sensory potentials.
      explanation: The eight-family cohort establishes sensory neuronopathy, with ascertainment focused on that presentation.
- name: Impaired Vibration Sense
  category: Neurologic
  phenotype_term:
    preferred_term: Impaired vibratory sensation
    term:
      id: HP:0002495
      label: Impaired vibratory sensation
  description: Vibration sense can be impaired in the sensory-neuronopathy presentation.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: early-onset progressive sensory ataxia, loss of position and vibration sense, absent tendon reflexes
    explanation: The cohort phenotype includes vibration loss.
  sequelae:
  - target: Ataxia
    description: Loss of sensory feedback contributes to the sensory component of ataxia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33751098
      reference_title: Bi-allelic loss of function variants in COX20 gene cause autosomal recessive sensory neuronopathy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: All patients displayed sensory ataxia with a decrease in non-length-dependent sensory potentials.
      explanation: The eight-family cohort establishes sensory neuronopathy, with ascertainment focused on that presentation.
- name: Limb Weakness
  category: Musculoskeletal
  phenotype_term:
    preferred_term: Limb muscle weakness
    term:
      id: HP:0003690
      label: Limb muscle weakness
  description: Proximal or distal limb weakness can accompany the neuropathy; severity varies.
  evidence:
  - reference: PMID:35651336
    reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Profound symmetric proximal muscle weakness of the lower limbs with 2–3/5 grades using the Medical Research Council (MRC) scale was noted.
    explanation: The older sibling had severe proximal lower-limb weakness.
- name: Motor Delay
  category: Neurologic
  phenotype_term:
    preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  description: Delayed walking occurs in some children, while others initially meet milestones.
  evidence:
  - reference: PMID:35651336
    reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Her motor development milestone was delayed. She was unable to walk until 1.5 years
    explanation: The younger sibling had motor delay.
- name: Intellectual Disability
  category: Neurologic
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  description: Cognition is variable, ranging from normal to mild intellectual disability or later decline.
  evidence:
  - reference: PMID:30656193
    reference_title: Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: He had mild cognitive disability and required special education throughout his schooling.
    explanation: Subject 3 had a persistent mild cognitive disability.
- name: Spasticity
  category: Neurologic
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  description: Central motor signs can coexist with peripheral areflexia.
  evidence:
  - reference: PMID:30656193
    reference_title: Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Her gait was significant for some toe walking associated with spasticity.
    explanation: Subject 1 showed spasticity.
- name: Visual Impairment
  category: Ophthalmologic
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  description: Reduced acuity is reported, sometimes despite normal fundus and visual-evoked studies; optic atrophy is not established by these reports.
  evidence:
  - reference: PMID:35651336
    reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Her visual acuity in the right eye was reduced to counting fingers and to 0.15 in the left eye.
    explanation: The older sibling had marked visual loss.
- name: Strabismus
  category: Ophthalmologic
  phenotype_term:
    preferred_term: Strabismus
    term:
      id: HP:0000486
      label: Strabismus
  description: Strabismus has been reported in several independent families.
  evidence:
  - reference: PMID:35651336
    reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Left-sided ptosis and strabismus were observed at first sight
    explanation: The older sibling had both ocular findings.
- name: Ptosis
  category: Ophthalmologic
  phenotype_term:
    preferred_term: Ptosis
    term:
      id: HP:0000508
      label: Ptosis
  description: Unilateral ptosis was documented in the older sibling of the ophthalmology series.
  evidence:
  - reference: PMID:35651336
    reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Left-sided ptosis and strabismus were observed at first sight
    explanation: The clinical examination documents left ptosis.
- name: Cerebellar Atrophy
  category: Neurologic
  phenotype_term:
    preferred_term: Cerebellar atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
  description: Cerebellar atrophy is documented in some patients; normal brain MRI is also common.
  evidence:
  - reference: PMID:32606554
    reference_title: 'Dysarthria, Ataxia, and Dystonia Associated with COX20 (FAM36A) Gene Mutation: A Case Report of a Turkish Child.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cerebral magnetic resonance imaging (MRI) showed cerebellar atrophy
    explanation: The Turkish child had cerebellar atrophy with normal nerve-conduction studies.
- name: Cervical Spinal Cord Atrophy
  category: Neurologic
  phenotype_term:
    preferred_term: Cervical spinal cord atrophy
    term:
      id: HP:0010873
      label: Cervical spinal cord atrophy
  description: Cervical and thoracic cord atrophy can occur without cerebellar atrophy.
  evidence:
  - reference: PMID:41010014
    reference_title: Mitochondrial Complex IV Deficiency Nuclear Type 11 Caused by a Novel Start-Lost Variant in the COX20 Gene.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Spinal cord MRI performed at the age of 20 years demonstrated cervical and thoracic cord atrophy
    explanation: The adult case directly documents the cervical localization.
- name: Pes Cavus
  category: Musculoskeletal
  phenotype_term:
    preferred_term: Pes cavus
    term:
      id: HP:0001761
      label: Pes cavus
  description: Cavus deformity occurs in some neuropathic presentations.
  evidence:
  - reference: PMID:30656193
    reference_title: Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Her left foot had a pes cavus deformity.
    explanation: Subject 1 had unilateral cavus deformity.
- name: Pes Planus
  category: Musculoskeletal
  phenotype_term:
    preferred_term: Pes planus
    term:
      id: HP:0001763
      label: Pes planus
  description: Flat feet occur in other patients, reflecting variable foot deformities.
  evidence:
  - reference: PMID:35651336
    reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: On neurological examination at 6 years, leg dystonia was observed, and she was found to be flat-footed
    explanation: The younger sibling had pes planus.
- name: Foot Drop
  category: Musculoskeletal
  phenotype_term:
    preferred_term: Foot dorsiflexor weakness
    term:
      id: HP:0009027
      label: Foot dorsiflexor weakness
  description: Foot dorsiflexor weakness can develop during childhood.
  evidence:
  - reference: PMID:30656193
    reference_title: Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: She developed bilateral foot drop at age 11 years.
    explanation: Subject 2 developed bilateral foot drop.
- name: Chorea
  category: Neurologic
  phenotype_term:
    preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  description: Choreiform movements have been reported in an affected adult.
  evidence:
  - reference: PMID:30656193
    reference_title: Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: He also developed frequent choreiform movements.
    explanation: Subject 3 had choreiform movements.
- name: Intention Tremor
  category: Neurologic
  phenotype_term:
    preferred_term: Intention tremor
    term:
      id: HP:0002080
      label: Intention tremor
  description: Intention tremor may accompany cerebellar signs.
  evidence:
  - reference: PMID:32606554
    reference_title: 'Dysarthria, Ataxia, and Dystonia Associated with COX20 (FAM36A) Gene Mutation: A Case Report of a Turkish Child.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: he had dysarthria, bilateral dysmetria, intention tremor, dysdiadochokinesia, and gait ataxia.
    explanation: The case documents intention tremor.
- name: Hearing Impairment
  category: Audiologic
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  description: Hearing loss was reported in one girl; the source does not establish its physiological subtype or frequency.
  evidence:
  - reference: PMID:32999401
    reference_title: Expanding the genotype-phenotype correlation of childhood sensory polyneuropathy of genetic origin.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: An 18-year-old girl with sensory neuropathy, ataxia, distal extremity weakness, spasticity, and hearing loss
    explanation: The COX20-specific case paragraph, rather than the mixed-gene cohort total, supports hearing impairment.
- name: Depression
  category: Psychiatric
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  description: Mood symptoms may complicate severe progressive disability.
  evidence:
  - reference: PMID:30656193
    reference_title: Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: she developed depression, which responded to Selective Serotonin Reuptake Inhibitor treatment
    explanation: Subject 2 had depression with a reported treatment response.
- name: Cerebral Atrophy
  category: Neurologic
  phenotype_term:
    preferred_term: Cerebral atrophy
    term:
      id: HP:0002059
      label: Cerebral atrophy
  description: Mild cerebral atrophy has been reported in a subset of cases; imaging can otherwise be normal.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Brain MRIs showed marginal cerebral atrophy in five patients and cerebellar atrophy in two patients.
    explanation: The literature compilation documents cerebral involvement.
    quote_role: REVIEW_SYNTHESIS
- name: Elevated Lactate
  category: Metabolic
  phenotype_term:
    preferred_term: Increased circulating lactate concentration
    term:
      id: HP:0002151
      label: Increased circulating lactate concentration
  description: Mild serum lactate elevation is inconsistent and is not a required diagnostic feature.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Standard laboratory analyses detected mildly elevated serum lactate levels in 4/17 of patients (23.5%)
    explanation: The count is limited to tested published cases.
    quote_role: REVIEW_SYNTHESIS
- name: Microcephaly
  category: Head and Neck
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  description: Microcephaly was reported in the founding child and is not a universal feature.
  evidence:
  - reference: PMID:30656193
    reference_title: Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: One family had a child with additional findings of microcephaly, mildly elevated serum and CSF lactate, and a normal brain MRI.
    explanation: Otero summarizes the founding case; this is secondary clinical evidence.
    quote_role: BACKGROUND
- name: Urinary Incontinence
  category: Genitourinary
  phenotype_term:
    preferred_term: Urinary incontinence
    term:
      id: HP:0000020
      label: Urinary incontinence
  description: Bladder-control difficulties can emerge with advanced neurological disability.
  evidence:
  - reference: PMID:30656193
    reference_title: Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: She became nonambulatory and developed incontinence at 19 years.
    explanation: Subject 2 developed incontinence; subject 4 also had bladder-control difficulties.
- name: Static Encephalopathy
  category: Neurologic
  phenotype_term:
    preferred_term: Static encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
    clinical_course: STABLE
  description: Static encephalopathy accompanied sensory-dominant axonal neuropathy in the Xu family. Static refers to the encephalopathy, not to a universally stable course of the motor disorder.
  evidence:
  - reference: PMID:31079202
    reference_title: Observation of novel COX20 mutations related to autosomal recessive axonal neuropathy and static encephalopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: two patients from a non-consanguineous family exhibiting autosomal recessive sensory-dominant axonal neuropathy and static encephalopathy
    explanation: Xu et al. describe static encephalopathy in two siblings; this is distinct from progressive gait impairment or a generic intellectual-disability label.
- name: Painful Muscle Spasms
  category: Musculoskeletal
  phenotype_term:
    preferred_term: Painful muscle spasms
    term:
      id: HP:0003394
      label: Muscle spasm
  description: Painful muscle spasms developed in adulthood in one reported patient. Spasms are distinguished from the separately observed spasticity.
  evidence:
  - reference: PMID:30656193
    reference_title: Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In her 20s, she developed painful muscle spasms that were treated with baclofen.
    explanation: Subject 2 developed painful spasms; the source does not establish that spasticity was the treated symptom.
genetic:
- name: Biallelic COX20 variants
  gene_term:
    preferred_term: COX20
    term:
      id: hgnc:26970
      label: COX20
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  features: Splice-disrupting, missense, nonsense and reported start-loss variants cause a variable recessive phenotype. The c.41A>G allele is recurrent and a shared haplotype supports an eastern Chinese founder effect. The linked p.Gly114Ser variant in the Otero families was considered likely benign and is not assigned causality.
  variants:
  - name: COX20 c.41A>G (p.Lys14Arg)
    description: Recurrent coding-position splice-disrupting variant; exon-1 deletion creates p.Gly8ValfsTer2. A protein-only K14R construct does not reproduce the splice effect.
    gene:
      preferred_term: COX20
      term:
        id: hgnc:26970
        label: COX20
    evidence:
    - reference: PMID:35651336
      reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: TA clone sequencing demonstrated that aligned with the reference sequence (NM_198076.6), the c.41A > G mutation led to a 20 bp deletion in exon 1.
      explanation: Patient-fibroblast transcript sequencing demonstrates the splice effect of the coding-position variant.
    - reference: PMID:31079202
      reference_title: Observation of novel COX20 mutations related to autosomal recessive axonal neuropathy and static encephalopathy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: sequencing analysis revealed that both patients harbored compound heterozygous mutations (p.Lys14Arg and p.Trp74Cys) of COX20 gene.
      explanation: The 2019 report supplies the original compound-heterozygous family observation, separately from later functional studies.
    variant_type: single nucleotide variant
  - name: COX20 c.157+3G>C
    description: Splice-donor-region variant associated with exon-2 skipping and loss of full-length RNA.
    gene:
      preferred_term: COX20
      term:
        id: hgnc:26970
        label: COX20
    evidence:
    - reference: PMID:30656193
      reference_title: Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: One variant (IVS2+3G>C), located near intron-2’s splice donor site, resulted in increased expression of the ΔEXON2 mRNA.
      explanation: Patient RNA supports altered splicing.
    variant_type: single nucleotide variant
    genomic_contexts:
    - intron
  - name: COX20 c.154A>C (p.Thr52Pro)
    description: Founding homozygous variant with reduced protein and altered transcript splicing.
    gene:
      preferred_term: COX20
      term:
        id: hgnc:26970
        label: COX20
    evidence:
    - reference: PMID:24202787
      reference_title: Recessive dystonia-ataxia syndrome in a Turkish family caused by a COX20 (FAM36A) mutation.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: By exome sequencing, we identified a homozygous missense mutation (c.154A >C; p.Thr52Pro) in both patients in exon 2 of the COX20 (FAM36A) gene
      explanation: The two siblings carried the founding allele.
    variant_type: single nucleotide variant
  - name: COX20 p.Ser33Leu and p.Trp74Cys
    description: Missense substitutions with accelerated turnover in expression assays; W74C is encoded by c.222G>T.
    gene:
      preferred_term: COX20
      term:
        id: hgnc:26970
        label: COX20
    evidence:
    - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
      reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: mutant COX20, especially W74C-COX20, were degraded faster than wild-type, suggesting that the two missense variants affected the protein half-life of COX20.
      explanation: Cycloheximide-chase experiments support instability of S33L and W74C proteins.
    - reference: PMID:31079202
      reference_title: Observation of novel COX20 mutations related to autosomal recessive axonal neuropathy and static encephalopathy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: sequencing analysis revealed that both patients harbored compound heterozygous mutations (p.Lys14Arg and p.Trp74Cys) of COX20 gene.
      explanation: The 2019 report supplies the original compound-heterozygous family observation, separately from later functional studies.
    variant_type: single nucleotide variant
  - name: COX20 c.157+7A>G
    description: A minigene assay, performed because patient RNA was unavailable, showed exon-2 skipping.
    gene:
      preferred_term: COX20
      term:
        id: hgnc:26970
        label: COX20
    evidence:
    - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
      reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: variant therefore caused the skipping of exon 2 resulting in a premature stop codon p.Ser15Valfs*11.
      explanation: The result is from a transfected minigene, not patient RNA.
    variant_type: single nucleotide variant
    genomic_contexts:
    - intron
  - name: COX20 c.42+1G>A
    description: Splice-donor variant reported in trans with c.41A>G; both affect the exon-1 donor.
    gene:
      preferred_term: COX20
      term:
        id: hgnc:26970
        label: COX20
    evidence:
    - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
      reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: cause a uniform splice defect of exon 1 resulting in a 20-base pair cDNA deletion at the 3′ end in more than 90% of the transcripts
      explanation: Patient RNA/proteomics support the combined splice defect.
    variant_type: single nucleotide variant
    genomic_contexts:
    - intron
  - name: COX20 c.259C>T (p.Gln87Ter)
    description: Nonsense allele found in trans with c.41A>G in multiple families.
    gene:
      preferred_term: COX20
      term:
        id: hgnc:26970
        label: COX20
    evidence:
    - reference: PMID:39897410
      reference_title: 'Prenatal Counseling and Diagnosis of COX20 Gene-Related Mitochondrial Complex IV Deficiency: A Case Report and Literature Review.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: whole-exome sequencing (WES) revealed compound heterozygous mutations in the COX20 gene (c.41A>G, p.Lys14Arg and c.259C>T, p.Gln87Ter)
      explanation: The prenatal-counseling family supplies unambiguous variant notation.
    variant_type: single nucleotide variant
  - name: COX20 c.2T>C (p.Met1?)
    description: Start-loss allele reported in a 2025 patient on NM_198076.6. The authors classified it as pathogenic, while earlier ClinVar submissions were uncertain; complete loss of expression was predicted rather than experimentally shown.
    gene:
      preferred_term: COX20
      term:
        id: hgnc:26970
        label: COX20
    evidence:
    - reference: PMID:41010014
      reference_title: Mitochondrial Complex IV Deficiency Nuclear Type 11 Caused by a Novel Start-Lost Variant in the COX20 Gene.
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: In silico analysis revealed the absence of downstream in-frame methionine codons
      explanation: The proposed loss of translation rests on sequence analysis, not a functional protein assay.
    variant_type: single nucleotide variant
  inheritance:
  - name: Autosomal recessive
    description: When both parents carry a causative allele, each pregnancy has a 25% affected risk, 50% carrier risk and 25% chance of inheriting neither familial allele.
    evidence:
    - reference: PMID:35651336
      reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The asymptomatic parents and sister of the patients were heterozygous carriers, following the characteristics of family segregation
      explanation: Segregation supports recessive inheritance.
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1224/
      reference_title: Primary Mitochondrial Disorders Overview - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: each sib of an affected individual has at conception a 25% chance of being affected
      explanation: The autosomal-recessive section applies when both parents carry a causative variant.
      quote_role: REVIEW_SYNTHESIS
  evidence:
  - reference: PMID:33751098
    reference_title: Bi-allelic loss of function variants in COX20 gene cause autosomal recessive sensory neuronopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We identified eight unrelated families from the eastern Chinese population carrying a founder variant c.41A>G (p.Lys14Arg) within COX20 in either a homozygous or compound heterozygous state.
    explanation: The shared haplotype supports a founder allele in this cohort, not a disease prevalence estimate.
  notes: ClinGen classified COX20-related mitochondrial disease as Definitive on 17 February 2022 under MONDO:0044970. That broader concept differs from the MONDO:0033645 binding of this entry, so the source is supporting context rather than a formal same-disease gene_disease_validity assertion.
treatments:
- name: Rehabilitation and communication support
  description: Physical, occupational and speech therapies support mobility, daily activities and communication. Mobility aids and orthotic assessment can be individualized; these measures have not been shown to stop COX20 disease progression.
  treatment_term:
    preferred_term: Rehabilitation
    term:
      id: NCIT:C15315
      label: Rehabilitation
  evidence:
  - reference: PMID:28749475
    reference_title: 'Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Therapy services including physical therapy, occupational therapy, and speech therapy
    explanation: The general mitochondrial consensus identifies these supportive services.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:39897410
    reference_title: 'Prenatal Counseling and Diagnosis of COX20 Gene-Related Mitochondrial Complex IV Deficiency: A Case Report and Literature Review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Despite intermittent treatment with L-carnitine and rehabilitation training, the patient’s symptoms progressed.
    explanation: Rehabilitation use in this child did not establish a disease-modifying effect.
  target_phenotypes:
  - preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  - preferred_term: Limb muscle weakness
    term:
      id: HP:0003690
      label: Limb muscle weakness
  - preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  - preferred_term: Foot dorsiflexor weakness
    term:
      id: HP:0009027
      label: Foot dorsiflexor weakness
- name: Levodopa trial for dystonia
  description: Responses differ. One six-year-old had improved gait for five months; her older sister did not respond to high-dose levodopa. Another patient did not respond to carbidopa/levodopa. These case observations support individualized assessment, not a predictable sustained benefit.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Levodopa
      term:
        id: NCIT:C611
        label: Levodopa
  evidence:
  - reference: PMID:35651336
    reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment with 62.5 mg levodopa effectively improved her gait but the effect lasted for only 5 months.
    explanation: A transient symptomatic benefit was reported in the younger sibling.
  - reference: PMID:35651336
    reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment with a high dose of L-DOPA was ineffective.
    explanation: The older sibling did not respond.
  - reference: PMID:30656193
    reference_title: Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: episodic dystonic posturing of her feet, which did not respond to carbidopa/levodopa treatment.
    explanation: Another patient had no reported dystonia benefit.
  target_phenotypes:
  - preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  therapeutic_modality: SMALL_MOLECULE
- name: Baclofen for painful spasms
  description: Baclofen has been used for painful muscle spasms. The published case does not quantify efficacy.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Baclofen
      term:
        id: NCIT:C28858
        label: Baclofen
  evidence:
  - reference: PMID:30656193
    reference_title: Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In her 20s, she developed painful muscle spasms that were treated with baclofen.
    explanation: The source documents use, not a demonstrated response.
  target_phenotypes:
  - preferred_term: Painful muscle spasms
    term:
      id: HP:0003394
      label: Muscle spasm
  therapeutic_modality: SMALL_MOLECULE
- name: Mental-health treatment
  description: Assess mood, cognition and behavior. Depression improved with an SSRI in one patient; later psychiatric symptoms required additional treatment. Medication choice and monitoring are individualized.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Selective Serotonin Reuptake Inhibitor
      term:
        id: NCIT:C94725
        label: Selective Serotonin Reuptake Inhibitor
  evidence:
  - reference: PMID:30656193
    reference_title: Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: she developed depression, which responded to Selective Serotonin Reuptake Inhibitor treatment
    explanation: The report documents a symptomatic antidepressant response.
  target_phenotypes:
  - preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
- name: Empirical mitochondrial supplements
  description: Coenzyme Q10 or idebenone, carnitine and vitamin combinations have been tried without consistent benefit. Reported two-year stability during supplementation can reflect natural history. These regimens are not established disease-modifying therapies.
  treatment_term:
    preferred_term: Nutritional Support
    term:
      id: NCIT:C15433
      label: Nutritional Support
    therapeutic_agent:
    - preferred_term: (R)-carnitine
      term:
        id: CHEBI:16347
        label: (R)-carnitine
    - preferred_term: Coenzyme Q10
      term:
        id: NCIT:C916
        label: Coenzyme Q10
    - preferred_term: Idebenone
      term:
        id: NCIT:C74158
        label: Idebenone
    - preferred_term: thiamine(1+)
      term:
        id: CHEBI:18385
        label: thiamine(1+)
  evidence:
  - reference: PMID:37095481
    reference_title: 'Clinical and genetic characteristics of children with COX20-associated mitochondrial disorder: case report and literature review.'
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: L-carnitine and coenzyme Q10 were administered to the patient, but the medication had no effect.
    explanation: The child had no reported benefit from this combination.
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: None showed any benefit from treatment.
    explanation: The immediately preceding paragraph describes two vitamin B1/idebenone/L-carnitine regimens and two muscle-relaxant regimens; these small observations do not establish universal inefficacy.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:41010014
    reference_title: Mitochondrial Complex IV Deficiency Nuclear Type 11 Caused by a Novel Start-Lost Variant in the COX20 Gene.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: Although no clinical improvement was observed, the patient’s condition remained stable throughout the two-year observation period. This stability, however, could be consistent with the natural history of the disease.
    explanation: The adult case does not establish that supplementation caused stability.
- name: Ophthalmological surveillance and visual support
  description: Assess acuity, ocular alignment and eye movements, and provide appropriate visual support. General mitochondrial guidance recommends ophthalmology assessment at diagnosis and annual follow-up; COX20-specific surveillance intervals have not been tested.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:28749475
    reference_title: 'Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Annual ophthalmology exams should be conducted thereafter.
    explanation: This follows the recommendation for neuro-ophthalmology assessment at diagnosis in general mitochondrial disease.
    quote_role: REVIEW_SYNTHESIS
  target_phenotypes:
  - preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  - preferred_term: External ophthalmoplegia
    term:
      id: HP:0000544
      label: External ophthalmoplegia
  - preferred_term: Strabismus
    term:
      id: HP:0000486
      label: Strabismus
  - preferred_term: Ptosis
    term:
      id: HP:0000508
      label: Ptosis
- name: Hearing assessment and rehabilitation
  description: Assess reported hearing difficulty and provide amplification when appropriate. These care options are extrapolated from general mitochondrial guidance.
  treatment_term:
    preferred_term: Rehabilitation
    term:
      id: NCIT:C15315
      label: Rehabilitation
  evidence:
  - reference: PMID:28749475
    reference_title: 'Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Moderate to severe hearing loss should be treated with digital hearing aids to improve function; when profound, cochlear implantation should be considered.
    explanation: General mitochondrial guidance supports hearing rehabilitation; COX20-specific treatment outcomes are unavailable.
    quote_role: REVIEW_SYNTHESIS
  target_phenotypes:
  - preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
- name: Multisystem surveillance
  description: Coordinate neurological, mobility, visual, hearing, cognitive and psychiatric follow-up. Broader mitochondrial guidance also supports cardiac and metabolic screening according to clinical context; these recommendations do not imply that each complication is common in COX20 deficiency.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1224/
    reference_title: Primary Mitochondrial Disorders Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: These focus on regular surveillance to detect complications and their management using standard approaches that are not usually specific to mitochondrial disorders.
    explanation: GeneReviews frames supportive care and surveillance.
    quote_role: REVIEW_SYNTHESIS
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1224/
    reference_title: Primary Mitochondrial Disorders Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Regular cardiac evaluation and monitoring for diabetes are particularly important.
    explanation: General mitochondrial surveillance is distinguished from COX20-specific phenotype frequencies.
    quote_role: REVIEW_SYNTHESIS
- name: Illness and perioperative planning
  description: Develop an individualized emergency plan, avoid prolonged fasting and review drug and anesthetic risks. Glucose-containing fluids require clinical adjustment for contraindications or prior adverse responses. Avoid prolonged propofol infusion where possible.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:28749475
    reference_title: 'Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Patients with a mitochondrial disease should carry an emergency care plan that details their underlying disorder and provides management recommendations.
    explanation: General mitochondrial guidance supports advance planning.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:28749475
    reference_title: 'Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Patients should minimize preoperative fasting and have glucose added to their perioperative IV fluids, unless they are on a ketogenic diet or have been demonstrated to have adverse reaction to higher glucose intake.
    explanation: Perioperative recommendations carry important exceptions.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:28749475
    reference_title: 'Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Mitochondrial patients may be at a higher risk for propofol infusion syndrome and propofol use should be avoided or limited to short procedures.
    explanation: General anesthetic caution is not a reported COX20-specific adverse event.
    quote_role: REVIEW_SYNTHESIS
- name: Genetic and reproductive counseling
  description: Confirm parental segregation and discuss the 25% affected risk per pregnancy when both parents carry causative alleles. Familial carrier testing, prenatal diagnosis and preimplantation testing are options according to family preferences; a published COX20 family underwent prenatal diagnosis, not preimplantation testing.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1224/
    reference_title: Primary Mitochondrial Disorders Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Carrier testing for at-risk relatives requires prior identification of the causative pathogenic variants in the family.
    explanation: General recessive mitochondrial counseling supports targeted familial testing.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:39897410
    reference_title: 'Prenatal Counseling and Diagnosis of COX20 Gene-Related Mitochondrial Complex IV Deficiency: A Case Report and Literature Review.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: parents may opt for preimplantation genetic diagnosis (PGD) during in vitro fertilization (IVF)
    explanation: The report discusses a reproductive option rather than documenting its use in this family.
    quote_role: REVIEW_SYNTHESIS
notes: Clinical subgroups describe overlapping presentations, not proven distinct molecular diseases. Population prevalence, penetrance and a reliable genotype-prognosis relationship have not been established. The general mitochondrial GeneReviews chapter provides clinical context; its broader phenotype frequencies and mitochondrial-DNA inheritance rules do not describe this nuclear-gene disorder.
has_subtypes:
- name: Infantile hypotonia presentation
  description: Infantile hypotonia and developmental or movement abnormalities without prominent neuropathy at assessment. Neuropathy can be absent or evolve later.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Only 3/27 patients (11.4%) presented with infantile hypotonia immediately after birth.
    explanation: The authors proposed a descriptive phenotype cluster; boundaries are not a validated genotype-based taxonomy.
    quote_role: REVIEW_SYNTHESIS
- name: Childhood axonal neuropathy presentation
  description: Childhood sensory-predominant axonal neuropathy, frequently with ataxia and variable motor involvement.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: patients (20/27 patients, 74.1%) present with axonal neuropathy and associated clinical signs, with an onset age ranging from 1 to 17 years;
    explanation: The authors proposed a descriptive phenotype cluster; boundaries are not a validated genotype-based taxonomy.
    quote_role: REVIEW_SYNTHESIS
- name: Neuropathy and dystonia-ataxia overlap
  description: Overlapping neuropathy, dystonia and cerebellar manifestations, often with later emergence of dystonia.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: a third group (4/27 patients; 14.8%) present with a neuropathy/DYTCA overlapping syndrome with an onset age ranging from 1.9 to 12 years.
    explanation: The authors proposed a descriptive phenotype cluster; boundaries are not a validated genotype-based taxonomy.
    quote_role: REVIEW_SYNTHESIS
diagnosis:
- name: Molecular confirmation
  diagnosis_term:
    preferred_term: DNA Sequencing
    term:
      id: NCIT:C153598
      label: DNA Sequencing
  description: Identify biallelic causative COX20 variants with a panel that includes COX20, exome or genome sequencing, and segregation testing. A negative panel that omitted COX20 does not exclude it.
  evidence:
  - reference: PMID:35651336
    reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Exome sequencing revealed two compound heterozygous variants of the COX20 gene (c.222G > T and c.41A > G) that co-segregated with the disorder in both patients.
    explanation: Exome analysis and family segregation established the molecular diagnosis.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1224/
    reference_title: Primary Mitochondrial Disorders Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Molecular genetic testing is used to establish the diagnosis.
    explanation: General mitochondrial guidance supports molecular confirmation.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:41010014
    reference_title: Mitochondrial Complex IV Deficiency Nuclear Type 11 Caused by a Novel Start-Lost Variant in the COX20 Gene.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: a gene panel for hereditary neuropathies, which did not include the COX20 gene, revealed no significant findings.
    explanation: The negative earlier panel had a gene-content limitation.
- name: Nerve-conduction studies
  diagnosis_term:
    preferred_term: Nerve Conduction Velocity Test
    term:
      id: NCIT:C88502
      label: Nerve Conduction Velocity Test
  description: Assess sensory amplitudes and distribution alongside motor conduction. Sensory studies may be normal early, so repeat testing is appropriate when the clinical syndrome progresses.
  evidence:
  - reference: PMID:37095481
    reference_title: 'Clinical and genetic characteristics of children with COX20-associated mitochondrial disorder: case report and literature review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: At the age of 4.5, the patient underwent magnetic resonance imaging (MRI) and nerve conduction tests, but all the results were normal.
    explanation: The initial study was normal.
  - reference: PMID:37095481
    reference_title: 'Clinical and genetic characteristics of children with COX20-associated mitochondrial disorder: case report and literature review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: However, the examination of nerve conduction performed on him again revealed severe axonal sensory neuropathy.
    explanation: Repeat testing at age five demonstrated the evolving sensory neuropathy.
- name: Brain and spinal MRI
  diagnosis_term:
    preferred_term: Magnetic Resonance Imaging
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
  description: Assess cerebellar, cerebral and spinal changes when indicated. Cord atrophy may coexist with normal cerebellar imaging, and entirely normal MRI does not exclude the disorder.
  evidence:
  - reference: PMID:41010014
    reference_title: Mitochondrial Complex IV Deficiency Nuclear Type 11 Caused by a Novel Start-Lost Variant in the COX20 Gene.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cerebellar atrophy was absent on all imaging studies
    explanation: The adult case had normal cerebellar structure despite cord atrophy.
  - reference: PMID:41010014
    reference_title: Mitochondrial Complex IV Deficiency Nuclear Type 11 Caused by a Novel Start-Lost Variant in the COX20 Gene.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Spinal cord MRI performed at the age of 20 years demonstrated cervical and thoracic cord atrophy
    explanation: Both cord regions were involved.
  - reference: PMID:37095481
    reference_title: 'Clinical and genetic characteristics of children with COX20-associated mitochondrial disorder: case report and literature review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: An MRI of his brain and spine showed a normal result.
    explanation: The child had genetically confirmed disease despite normal imaging.
- name: Lactate testing
  diagnosis_term:
    preferred_term: Lactic Acid Measurement
    term:
      id: NCIT:C79450
      label: Lactic Acid Measurement
  description: Lactate can be elevated but is often normal. A normal concentration does not exclude mitochondrial disease or COX20 deficiency.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Standard laboratory analyses detected mildly elevated serum lactate levels in 4/17 of patients (23.5%)
    explanation: Only a minority of tested cases in the literature compilation had elevated lactate.
    quote_role: REVIEW_SYNTHESIS
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1224/
    reference_title: Primary Mitochondrial Disorders Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Normal plasma or CSF lactic acid concentration does not exclude the presence of a mitochondrial disorder.
    explanation: GeneReviews explicitly cautions against exclusion on a normal lactate result.
    quote_role: REVIEW_SYNTHESIS
- name: Tissue and cellular functional studies
  diagnosis_term:
    preferred_term: Respiratory-chain enzymology and complex IV assembly analysis
  description: Respiratory-chain enzymology, COX histochemistry, immunoblotting, blue-native electrophoresis and RNA studies can support variant interpretation. Sensitivity differs by assay, tissue and genotype; normal fibroblast OXPHOS does not negate a molecular diagnosis.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: an isolated complex IV defect in the skeletal muscle of two patients
    explanation: The literature review describes reduced complex IV activity in patient muscle tissue.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:23125284
    reference_title: A mutation in the FAM36A gene, the human ortholog of COX20, impairs cytochrome c oxidase assembly and is associated with ataxia and muscle hypotonia.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Cells affected by the mutation accumulate subassemblies of complex IV that contain COX1 but are almost devoid of COX2 protein.
    explanation: Patient-fibroblast subassemblies demonstrate failed incorporation of COX2.
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
    supports: REFUTE
    evidence_source: IN_VITRO
    snippet: normal OXPHOS activity in the fibroblasts of three patients
    explanation: These cultured-fibroblast results refute universal assay-detectable deficiency. Together with reduced activity in other tissues and lines they support the Variable presence annotation, not reduced activity in these three cultures.
    quote_role: REVIEW_SYNTHESIS
  notes: The composite combines enzyme assays, protein-complex analysis and RNA studies. NCIT search 'l~Enzyme Activity' returns the activity concept NCIT:C180567, which is not a diagnostic procedure; it is not substituted for this combination.
- name: Prenatal familial-variant testing
  diagnosis_term:
    preferred_term: Prenatal molecular testing of familial COX20 variants
    term:
      id: NCIT:C15709
      label: Genetic Testing
  description: After defining familial variants, prenatal testing can determine fetal genotype. Amniocentesis identified an affected fetus and chorionic-villus testing in a later pregnancy identified a heterozygous carrier in one reported family. Testing and reproductive decisions require nondirective counseling.
  evidence:
  - reference: PMID:39897410
    reference_title: 'Prenatal Counseling and Diagnosis of COX20 Gene-Related Mitochondrial Complex IV Deficiency: A Case Report and Literature Review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the mother of the patient underwent amniocentesis during a subsequent pregnancy. The procedure confirmed that the fetus carried identical mutations in the COX20 gene as the proband.
    explanation: A family received prenatal molecular testing.
  - reference: PMID:39897410
    reference_title: 'Prenatal Counseling and Diagnosis of COX20 Gene-Related Mitochondrial Complex IV Deficiency: A Case Report and Literature Review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: WES detected only the heterozygous mutation c.41A>G (p.Lys14Arg), consistent with the maternal genotype.
    explanation: A subsequent chorionic-villus sample was heterozygous, followed by birth of an unaffected child.
experimental_models:
- name: COX20-depleted HEK293T cells
  experimental_model_type: CELL_LINE
  description: siRNA and TALEN-based COX20 depletion demonstrate rapid COX2 turnover, assembly intermediates and residual complex IV activity. COX20-FLAG permits rescue and interaction studies.
  evidence:
  - reference: PMID:24403053
    reference_title: Human COX20 cooperates with SCO1 and SCO2 to mature COX2 and promote the assembly of cytochrome c oxidase.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: newly synthesized COX2 is unstable and most of it is rapidly degraded within 2 h of the chase
    explanation: Pulse-chase analysis in COX20-silenced cells identifies reduced COX2 stability rather than a primary synthesis defect.
  - reference: PMID:24403053
    reference_title: Human COX20 cooperates with SCO1 and SCO2 to mature COX2 and promote the assembly of cytochrome c oxidase.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We propose that COX20 acts as a chaperone in the early steps of COX2 maturation, stabilizing the newly synthesized protein and presenting COX2 to its metallochaperone module
    explanation: Protein-interaction experiments motivate the COX2 presentation model; direct copper transport by COX20 is not established.
    directness: INDIRECT
  modeled_mechanisms:
  - target: COX2 Instability
    relationship: RECAPITULATES
    description: Pulse-chase analysis shows rapid COX2 turnover.
    evidence:
    - reference: PMID:24403053
      reference_title: Human COX20 cooperates with SCO1 and SCO2 to mature COX2 and promote the assembly of cytochrome c oxidase.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: newly synthesized COX2 is unstable and most of it is rapidly degraded within 2 h of the chase
      explanation: Pulse-chase analysis in COX20-silenced cells identifies reduced COX2 stability rather than a primary synthesis defect.
    model_scale: CELLULAR
    fidelity: MODERATE
    limitations: Culture findings do not establish clinical treatment efficacy or the full neurological phenotype.
  - target: Reduced Complex IV Assembly
    relationship: RECAPITULATES
    description: Engineered cells accumulate assembly intermediates.
    evidence:
    - reference: PMID:24403053
      reference_title: Human COX20 cooperates with SCO1 and SCO2 to mature COX2 and promote the assembly of cytochrome c oxidase.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Mitochondria lacking COX20 accumulate CIV subassemblies containing COX1 and COX4
      explanation: The engineered human-cell system reproduces the assembly lesion.
    model_scale: CELLULAR
    fidelity: MODERATE
    limitations: Culture findings do not establish clinical treatment efficacy or the full neurological phenotype.
- name: Patient fibroblast complementation
  experimental_model_type: PRIMARY_CELL_CULTURE
  description: Patient fibroblasts support RNA, protein, assembly and respiratory analyses. Wild-type lentiviral or adenoviral COX20 restores cellular function in reported lines; other patients can have normal routine enzyme assays.
  evidence:
  - reference: PMID:30656193
    reference_title: Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Consistent with this finding, protein analysis revealed no detectable COX20 protein present
    explanation: Immunoblotting of patient fibroblasts demonstrates loss of detectable COX20.
  - reference: PMID:23125284
    reference_title: A mutation in the FAM36A gene, the human ortholog of COX20, impairs cytochrome c oxidase assembly and is associated with ataxia and muscle hypotonia.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Lentiviral complementation of patient's fibroblasts with wild-type FAM36A increases the complex IV activity as well as the amount of holocomplex IV and of individual subunits.
    explanation: Genetic complementation supports COX20 causality in culture.
  - reference: PMID:35651336
    reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Overexpression of COX20 using a transduced adenovirus partially restored the function of the patients' fibroblasts.
    explanation: This is cell complementation, not a clinical gene-therapy trial.
  modeled_mechanisms:
  - target: Reduced Complex IV Assembly
    relationship: RESCUES
    description: Wild-type COX20 increases assembled complex IV.
    evidence:
    - reference: PMID:23125284
      reference_title: A mutation in the FAM36A gene, the human ortholog of COX20, impairs cytochrome c oxidase assembly and is associated with ataxia and muscle hypotonia.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Lentiviral complementation of patient's fibroblasts with wild-type FAM36A increases the complex IV activity as well as the amount of holocomplex IV and of individual subunits.
      explanation: Genetic complementation supports COX20 causality in culture.
    model_scale: CELLULAR
    fidelity: MODERATE
    limitations: Culture findings do not establish clinical treatment efficacy or the full neurological phenotype.
  - target: Reduced Respiratory Reserve
    relationship: RESCUES
    description: Adenoviral COX20 partially restores mitochondrial function.
    evidence:
    - reference: PMID:35651336
      reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Overexpression of COX20 using a transduced adenovirus partially restored the function of the patients' fibroblasts.
      explanation: This is cell complementation, not a clinical gene-therapy trial.
    model_scale: CELLULAR
    fidelity: MODERATE
    limitations: Culture findings do not establish clinical treatment efficacy or the full neurological phenotype.
- name: COX20-silenced ND7/23 cells
  experimental_model_type: CELL_LINE
  description: Two lentiviral-shRNA knockdown clones model respiratory and stress phenotypes in a sensory-neuron-like line. The stronger clone shows the clearer assembled-complex-IV and peroxide-viability abnormalities.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: knockdown of COX20 expression resulted in the reduction of ATP-linked OCR and maximal respiration OCR, indicating a lower spare respiratory capacity.
    explanation: Respirometry demonstrates reduced ATP-linked respiration and reserve in ND7/23 cultures; it does not establish total ATP collapse.
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: growth rate was significantly lower in siCOX20 cells than that in control cells in regular glucose medium, and further decreased in oxidative phosphorylation-promoting galactose media.
    explanation: COX20 silencing impairs cultured-cell growth, particularly when oxidative phosphorylation is required.
  modeled_mechanisms:
  - target: Reduced Respiratory Reserve
    relationship: RECAPITULATES
    description: Knockdown reduces ATP-linked respiration and reserve.
    evidence:
    - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
      reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: knockdown of COX20 expression resulted in the reduction of ATP-linked OCR and maximal respiration OCR, indicating a lower spare respiratory capacity.
      explanation: Respirometry demonstrates reduced ATP-linked respiration and reserve in ND7/23 cultures; it does not establish total ATP collapse.
    model_scale: CELLULAR
    fidelity: MODERATE
    limitations: Culture findings do not establish clinical treatment efficacy or the full neurological phenotype.
  - target: Reduced Cellular Stress Tolerance
    relationship: RECAPITULATES
    description: Galactose challenge accentuates the growth defect.
    evidence:
    - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
      reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: growth rate was significantly lower in siCOX20 cells than that in control cells in regular glucose medium, and further decreased in oxidative phosphorylation-promoting galactose media.
      explanation: COX20 silencing impairs cultured-cell growth, particularly when oxidative phosphorylation is required.
    model_scale: CELLULAR
    fidelity: MODERATE
    limitations: Culture findings do not establish clinical treatment efficacy or the full neurological phenotype.
- name: COX20 splice and protein-stability assays
  experimental_model_type: CELL_LINE
  description: Minigene analysis supports c.157+7A>G-associated exon-2 skipping; tagged-protein expression and cycloheximide chase distinguish S33L/W74C protein instability from the c.41A>G splice defect. Proteasome inhibition in these assays is not an established treatment.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: mutant COX20, especially W74C-COX20, were degraded faster than wild-type, suggesting that the two missense variants affected the protein half-life of COX20.
    explanation: Cycloheximide-chase experiments support instability of S33L and W74C proteins.
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We found that MG132 treatment rescued the degradation of already synthesized mutant proteins, particularly in S33L-COX20
    explanation: The proteasome experiment addresses mutant-protein turnover in transfected cells.
  modeled_mechanisms:
  - target: COX20 Protein Instability
    relationship: RECAPITULATES
    description: Mutant constructs turn over faster than wild type.
    evidence:
    - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
      reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: mutant COX20, especially W74C-COX20, were degraded faster than wild-type, suggesting that the two missense variants affected the protein half-life of COX20.
      explanation: Cycloheximide-chase experiments support instability of S33L and W74C proteins.
    model_scale: CELLULAR
    fidelity: MODERATE
    limitations: Culture findings do not establish clinical treatment efficacy or the full neurological phenotype.
datasets:
- accession: SRA:SRR18749879
  title: 'Illumina Genome Analyzer II sequencing: Exo-Seq of blood'
  description: Public sequencing run linked by Li et al. to the COX20 ophthalmoplegia/visual-failure family. The paper reports these two run accessions; individual sample assignment is not inferred.
  data_type: WES
  publication: PMID:35651336
  notes: ENA experiment title is reproduced verbatim. ENA labels the library strategy WGS, whereas its experiment title and the associated paper describe exome sequencing; WES follows the publication.
- accession: SRA:SRR18749880
  title: 'Illumina Genome Analyzer II sequencing: Exo-Seq of blood'
  description: Public sequencing run linked by Li et al. to the COX20 ophthalmoplegia/visual-failure family. The paper reports these two run accessions; individual sample assignment is not inferred.
  data_type: WES
  publication: PMID:35651336
  notes: ENA experiment title is reproduced verbatim. ENA labels the library strategy WGS, whereas its experiment title and the associated paper describe exome sequencing; WES follows the publication.
discussions:
- discussion_id: cox20-tissue-vulnerability
  prompt: Why do similar COX20 defects produce different central and peripheral neurological phenotypes?
  kind: OPEN_QUESTION
  status: OPEN
  rationale: Cellular respiratory defects and large-fiber pathology support bioenergetic disease, but genotype-severity relationships and the selective vulnerability of sensory neurons remain unresolved. Mouse single-cell expression analysis suggests enrichment in proprioceptive populations; this is computational context rather than proof of a human cell-specific mechanism.
  evidence:
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: was preferentially expressed in two proprioceptive populations (termed NF4 and NF5).
    explanation: The result comes from reanalysis of a mouse dorsal-root-ganglion single-cell database.
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Unfortunately, a clear genotype/phenotype correlation could not be established
    explanation: The literature synthesis explicitly identifies this limitation.
    quote_role: REVIEW_SYNTHESIS
references:
- reference: PMID:23125284
  title: A mutation in the FAM36A gene, the human ortholog of COX20, impairs cytochrome c oxidase assembly and is associated with ataxia and muscle hypotonia.
- reference: PMID:24202787
  title: Recessive dystonia-ataxia syndrome in a Turkish family caused by a COX20 (FAM36A) mutation.
- reference: PMID:24403053
  title: Human COX20 cooperates with SCO1 and SCO2 to mature COX2 and promote the assembly of cytochrome c oxidase.
- reference: PMID:28749475
  title: 'Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.'
- reference: PMID:30656193
  title: Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.
- reference: PMID:31079202
  title: Observation of novel COX20 mutations related to autosomal recessive axonal neuropathy and static encephalopathy.
- reference: PMID:32606554
  title: 'Dysarthria, Ataxia, and Dystonia Associated with COX20 (FAM36A) Gene Mutation: A Case Report of a Turkish Child.'
- reference: PMID:32999401
  title: Expanding the genotype-phenotype correlation of childhood sensory polyneuropathy of genetic origin.
- reference: PMID:33751098
  title: Bi-allelic loss of function variants in COX20 gene cause autosomal recessive sensory neuronopathy.
- reference: PMID:35651336
  title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
- reference: PMID:37095481
  title: 'Clinical and genetic characteristics of children with COX20-associated mitochondrial disorder: case report and literature review.'
- reference: PMID:39897410
  title: 'Prenatal Counseling and Diagnosis of COX20 Gene-Related Mitochondrial Complex IV Deficiency: A Case Report and Literature Review.'
- reference: PMID:41010014
  title: Mitochondrial Complex IV Deficiency Nuclear Type 11 Caused by a Novel Start-Lost Variant in the COX20 Gene.
- reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
  title: https://oup.silverchair-cdn.com/article-minimal/6180070
- reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
  title: https://oup.silverchair-cdn.com/article-minimal/6711551
- reference: url:https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_2391b81d-cfd2-4862-b71b-0418794539c3-2022-02-17T170000.000Z
  title: curation results for Gene-Disease Validity
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1224/
  title: Primary Mitochondrial Disorders Overview - GeneReviews® - NCBI Bookshelf
  tags:
  - GeneReviews
animal_models:
- name: Saccharomyces cerevisiae cox20 deletion
  species: Saccharomyces cerevisiae
  genotype: cox20 deletion
  description: The deletion produces a respiratory-growth defect rescued by native yeast Cox20 but not human COX20 despite mitochondrial import. Yeast Cox2 has a cleaved N-terminal precursor absent from human COX2, limiting direct functional interchangeability.
  evidence:
  - reference: PMID:24403053
    reference_title: Human COX20 cooperates with SCO1 and SCO2 to mature COX2 and promote the assembly of cytochrome c oxidase.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: ScCox20-HA complemented the respiratory defect of Δcox20 yeast, but the human protein did not
    explanation: Native yeast complementation supports the conserved respiratory role; lack of cross-species complementation limits extrapolation.
  modeled_mechanisms:
  - target: Reduced Complex IV Activity
    relationship: RECAPITULATES
    description: The model reproduces impaired respiratory function associated with Cox20 loss.
    evidence:
    - reference: PMID:24403053
      reference_title: Human COX20 cooperates with SCO1 and SCO2 to mature COX2 and promote the assembly of cytochrome c oxidase.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: ScCox20-HA complemented the respiratory defect of Δcox20 yeast, but the human protein did not
      explanation: Native yeast complementation supports the conserved respiratory role; lack of cross-species complementation limits extrapolation.
    model_scale: CELLULAR
    fidelity: MODERATE
    limitations: Yeast precursor processing differs from human COX2 maturation, and the model does not reproduce neurological disease.
histopathology:
- name: Large myelinated nerve-fiber depletion
  description: Sural nerve biopsy can show marked depletion of large myelinated fibers, with axonal degeneration in the 2021 series. Fiber loss alone should not be interpreted as proof of primary demyelination.
  evidence:
  - reference: PMID:35651336
    reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Pronounced depletion of large myelinated fibers by approximately 80% in the MGT-stained sural nerve
    explanation: The proband biopsy documents large-fiber loss; this does not by itself establish primary demyelination.
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6180070
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6180070
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Sural nerve biopsy in Patient 5 showed marked loss of large and medium myelinated fibres and chronic axonal degeneration
    explanation: The independent biopsy supports chronic axonal pathology.
- name: Muscle denervation atrophy
  description: Angulated atrophic muscle fibers without ragged-red fibers were seen in the older sibling in the 2022 visual-impairment report.
  evidence:
  - reference: PMID:35651336
    reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: numerous angulated atrophic fibers with an angular shape and decreased size, indicating atrophic fibers and denervation atrophy
    explanation: Muscle histology documents denervation rather than a universal primary myopathic pattern.
- name: Abnormal mitochondrial morphology in sural nerve
  description: The Xu family report described abnormal mitochondrial morphology in sural nerve tissue. Its abstract does not resolve the detailed ultrastructural changes.
  evidence:
  - reference: PMID:31079202
    reference_title: Observation of novel COX20 mutations related to autosomal recessive axonal neuropathy and static encephalopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: morphological alternations of mitochondria observed in sural nerve
    explanation: The source reports a morphological abnormality in patient nerve tissue; the source spelling is preserved.
biochemical:
- name: Reduced complex IV activity
  presence: Variable
  context: Assay and tissue dependent; muscle and some fibroblast lines are abnormal, while other fibroblast assays are normal.
  evidence:
  - reference: PMID:35651336
    reference_title: Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The enzyme activities of complex IV were lower in the patient's cells than in control cells
    explanation: Patient-fibroblast enzyme assays establish reduced complex IV activity.
  - reference: url:https://oup.silverchair-cdn.com/article-minimal/6711551
    reference_title: https://oup.silverchair-cdn.com/article-minimal/6711551
    supports: REFUTE
    evidence_source: IN_VITRO
    snippet: normal OXPHOS activity in the fibroblasts of three patients
    explanation: These cultured-fibroblast results refute universal assay-detectable deficiency. Together with reduced activity in other tissues and lines they support the Variable presence annotation, not reduced activity in these three cultures.
    quote_role: REVIEW_SYNTHESIS
- name: Reduced muscle coenzyme Q10
  presence: Reported in a family
  context: Documented in the Turkish sibling report; not established as a universal biochemical feature.
  evidence:
  - reference: PMID:24202787
    reference_title: Recessive dystonia-ataxia syndrome in a Turkish family caused by a COX20 (FAM36A) mutation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Biochemical analyses revealed a mitochondrial respiratory chain complex IV and a coenzyme Q10 deficiency in a muscle biopsy.
    explanation: The muscle assay found both abnormalities.

📚

References & Deep Research

References

17

PMID:23125284

A mutation in the FAM36A gene, the human ortholog of COX20, impairs cytochrome c oxidase assembly and is associated with ataxia and muscle hypotonia.

No top-level findings curated for this source.

PMID:24202787

Recessive dystonia-ataxia syndrome in a Turkish family caused by a COX20 (FAM36A) mutation.

No top-level findings curated for this source.

PMID:24403053

Human COX20 cooperates with SCO1 and SCO2 to mature COX2 and promote the assembly of cytochrome c oxidase.

No top-level findings curated for this source.

PMID:28749475

Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.

No top-level findings curated for this source.

PMID:30656193

Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy.

No top-level findings curated for this source.

PMID:31079202

Observation of novel COX20 mutations related to autosomal recessive axonal neuropathy and static encephalopathy.

No top-level findings curated for this source.

PMID:32606554

Dysarthria, Ataxia, and Dystonia Associated with COX20 (FAM36A) Gene Mutation: A Case Report of a Turkish Child.

No top-level findings curated for this source.

PMID:32999401

Expanding the genotype-phenotype correlation of childhood sensory polyneuropathy of genetic origin.

No top-level findings curated for this source.

PMID:33751098

Bi-allelic loss of function variants in COX20 gene cause autosomal recessive sensory neuronopathy.

No top-level findings curated for this source.

PMID:35651336

Compound Heterozygous COX20 Variants Impair the Function of Mitochondrial Complex IV to Cause a Syndrome Involving Ophthalmoplegia and Visual Failure.

No top-level findings curated for this source.

PMID:37095481

Clinical and genetic characteristics of children with COX20-associated mitochondrial disorder: case report and literature review.

No top-level findings curated for this source.

PMID:39897410

Prenatal Counseling and Diagnosis of COX20 Gene-Related Mitochondrial Complex IV Deficiency: A Case Report and Literature Review.

No top-level findings curated for this source.

PMID:41010014

Mitochondrial Complex IV Deficiency Nuclear Type 11 Caused by a Novel Start-Lost Variant in the COX20 Gene.

No top-level findings curated for this source.

url:https://oup.silverchair-cdn.com/article-minimal/6180070

https://oup.silverchair-cdn.com/article-minimal/6180070

No top-level findings curated for this source.

url:https://oup.silverchair-cdn.com/article-minimal/6711551

https://oup.silverchair-cdn.com/article-minimal/6711551

No top-level findings curated for this source.

url:https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_2391b81d-cfd2-4862-b71b-0418794539c3-2022-02-17T170000.000Z

curation results for Gene-Disease Validity

No top-level findings curated for this source.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1224/

Primary Mitochondrial Disorders Overview - GeneReviews® - NCBI Bookshelf

No top-level findings curated for this source.

COX20-Related COX Deficiency

Ask OpenScientist

OpenScientist Report

Classifications

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Diagnosis

Related Datasets

Experimental Models

Animal Models

Source YAML

References & Deep Research

References